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ABSTRACT
Progestagen is crucial for regulating early pregnancy in most mammalian species,
including the horse. This dissertation research sought to elucidate the effect of endogenous and
exogenous progestagens on the early development of equine embryos and to characterize
reproductive parameters in the subsequent estrus using a prostaglandin F2α-induced hypoluteal
environment, namely the aluteal pregnancy model. The first chapter reviewed the life cycle of the
corpus luteum and its progesterone secretory function in mares. The existing literature supports
the notion that the early developing corpus luteum is responsive to prostaglandin F2α, and complete
luteolysis or prevention of luteal formation can be achieved by using an appropriate treatment
regimen with prostaglandin F2α in mares. The second chapter investigated the effect of progestagen
deficiency or supplementation on early embryonic development using the aluteal pregnancy model
in mares. We found that developmentally retarded embryos with adequate quality could be
collected on day 7 after ovulation in aluteal cycles. Furthermore, a long-acting injectable
formulation of progestagen, altrenogest, could induce a favorable endometrial environment to
support adequate embryonic development until day 7, without the progestational support from the
corpus luteum. Nonetheless, compromised pregnancy was noted at a later stage on day 24 when
pregnancy was solely supported by the long-acting injectable altrenogest. The third chapter
described the profile of reproductive hormones in aluteal cycles with or without altrenogest
supplementation and delineated the reproductive parameters of the subsequent estrus. Mares in
aluteal cycles developed a characteristic hormonal profile of low plasma progesterone and
persistently elevated plasma luteinizing hormone. In the subsequent estrus developed under aluteal
environment, mares had an increased number of follicles and occurrence of multiple ovulations.
The fourth chapter investigated the effect of constant-rate infusion of prostaglandin F2α during the

vii

first 24 hours after ovulation on luteal function. This treatment regimen did not reduce the
interovulatory interval and concentrations of plasma progesterone in diestrus. Together, our
findings characterized the early embryonic development and reproductive parameters of pregnant
mares during luteal and aluteal cycles. Furthermore, effects on embryonic development and dam’s
reproductive endocrine profiles induced by the aluteal environment could be partially reverted by
altrenogest supplementation.

viii

CHAPTER 1. INTRODUCTION
1.1. General Introduction
Early pregnancy loss is a major cause of reproductive failure in mares. It is generally
deﬁned as the pregnancy failure that occurs between fertilization and days 40 to 60 of gestation
(Vanderwall 2008), which includes the early embryonic loss (up to day 35) and the losses during
the implantation period (days 40 to 60; Allen & Wilsher 2009). The reported incidence of early
pregnancy loss has ranged from 2.6 to 24.0% (Vanderwall 2008, Nath et al. 2010, Hanlon et al.
2012, Rose et al. 2018). Since the conceptus is too small to be detected before day 10 of gestation
by transrectal ultrasonography, embryonic losses in the first week of equine pregnancy have been
investigated via another invasive approach, i.e., collecting tubal-stage embryos via flank
laparotomy (Ball et al. 1986, Carnevale et al. 1993). Data have shown that the rate of embryonic
loss is approximately 30% for fertile mares, and it can be as high as 73% for subfertile mares (Ball
et al. 1986, Ball 1988). The cause of early pregnancy loss in the mare is multifactorial (Vanderwall
2008). Increased maternal age is associated with degenerative changes in the endometrium and
intrinsic defects of oocytes and embryos. Foal heat breeding and the presence of uterine cysts have
also been reported to increase the likelihood of early pregnancy loss in mares.
Equine pregnancy has an extensive period of preimplantation, at which the development
of the embryo is mainly supported by the secretion of endometrial glands, termed the histotroph
(Allen & Wilsher 2009). Progesterone secreted by the corpus luteum (CL) in the ovary plays an
essential role in establishing and maintaining the pregnancy by promoting uterine quiescence and
stimulating the production of histotroph (Aurich & Budik 2015). Therefore, luteal insufﬁciency
has been frequently suspected as one of the potential causes of early pregnancy loss (Ginther et al.
1985, Bergfelt et al. 1992). Researchers recently suggested that hypoluteoidism could be a more
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important cause for early pregnancy loss in mares than previously assumed (Betteridge et al. 2018).
Since the therapeutic options for mares with a history of early pregnancy loss are very limited,
horse breeders often request their veterinarians to prescribe progestational supplementation to their
mares, most of the time without measuring the mare’s blood progesterone. However, there is a
paucity of evidence showing the beneficial effect of supplementation of progestagens
(progesterone or synthetic progestins) on reducing the rate of early pregnancy loss in subfertile
mares.
This chapter reviews the life cycle of the CL and its progesterone secretory function in
mares. Relevant experimental models for studying hypoluteoidism in early equine pregnancy will
be introduced with the current evidence of the luteal sensitivity to luteolytic agents,
prostaglandin F2α (PGF2α), and its analog in early diestrus. The clinical use of progestagen
supplementation for early pregnant mares will also be discussed. Potential research areas will be
highlighted by evaluating the use of PGF2α in the early post-ovulatory period.
1.2. The Life Cycle of the Corpus Luteum
1.2.1. Luteogenesis: Formation of Corpus Luteum
The CL is a small, transient endocrine gland formed in the ovary following ovulation. The
main function of the CL is the production of progesterone by the luteal cells (Short 1962). This
reproductive hormone is vital for regulating the length of the estrous cycle and supports the
pregnancy. During estrus, plasma progesterone concentration is at its basal level due to the absence
of a functional CL. Before ovulation, granulosa and theca interna cells in the preovulatory follicle
begin to luteinize and produce progesterone in response to increasing blood concentrations of the
luteinizing hormone (LH). A significant increase in plasma progesterone level usually occurs
within 24 hours after ovulation, which reaches a plateau (>10 ng/mL) between five to six days
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after ovulation (Stabenfeldt et al. 1972, Townson et al. 1989). The CL continues to secrete
progesterone for approximately two weeks during the non-pregnant diestrus stage of the estrous
cycle. Plasma progesterone concentrations are typically higher after multiple ovulations compared
to single ovulation (Nagy et al. 2004), and higher in ponies compared to horse mares (Townson et
al. 1989).
The CL is typically formed following ovulation; however, the mechanism of luteinization
does not depend on the rupture of the follicle (Ginther et al. 2006). The actual stimulus for
luteinization is attributed to the increased level of LH released from the adenohypophysis before
ovulation occurs. Interestingly, mares have a steady increase in LH concentrations leading to
oocyte maturation and follicular rupture, compared with the well-defined LH surge before
ovulation in other domestic species. In mares, the increasing LH concentrations reach a peak
approximately a day or two after ovulation (Evans & Irvine 1975). Thus, luteinization of the
follicular cells, i.e., granulosa and theca interna cells, begins before ovulation. Immediately after
ovulation, granulosa cells rapidly undergo hypertrophy and hyperplasia. They continue to undergo
functional and structural changes that lead to significant growth of the CL. In contrast to other
domestic species, the theca interna cells are reported to not contribute to the formation and
secretory function of the CL, and these cells become atretic just after ovulation (Harrison 1946,
Van Niekerk et al. 1975, Sirois et al. 1991, Almadhidi et al. 1995).
Even when a mare experiences an ovulatory failure, e.g., forming a hemorrhagic
anovulatory follicle (HAF), the granulosa cells will differentiate and eventually become luteinized
in most cases (McCue & Squires 2002, Ginther et al. 2006, Ellenberger et al. 2009). A study
reported that some mares might have a slower increase in the concentration of serum progesterone
when they developed HAF (Lefranc & Allen 2003), while other studies found no difference in the
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progesterone profile between the mares with HAF and those with normal ovulation (Ginther et al.
2006, 2007a). Corpora lutea (CLs) may also be formed from unruptured follicles in pregnant mares
(Squires et al. 1974), under the stimulation of equine chorionic gonadotropin (eCG) secreted from
the developing endometrial cups (Daels et al. 1998). In addition, the development of functional
luteal tissue can also be induced artificially by aspiration or ablation of various sized antral follicles
(≥25mm) in mares (Hinrichs et al. 1991, Ignácio et al. 2021).
Primarily initiated by the increasing blood LH concentrations, the interaction between
immune, endothelial, and luteal steroidogenic cells is crucial for both the establishment and
regression of the CL (Galvão et al. 2013, Galvão et al. 2018). The development of the follicular
tissue into the fully developed CL is represented by extensive vascularization, extra-cellular matrix
(ECM) remodeling, and steroidogenesis (Pinto 2015). The CL undergoes extremely rapid growth
and intense angiogenesis that is tightly regulated by a balance between pro-angiogenic and
anti-angiogenic factors (Redmer & Reynolds 1996, Rieger et al. 2020). Although the rupture of
the follicular wall is not necessary for luteinization (Ginther et al. 2006), the disruption of the
basement membrane between the avascular granulosa layer and the highly vascularized theca layer
greatly facilitates the process of luteinization. The loss of integrity between these two layers
promotes the invasion of endothelial cells and other cell types, e.g., fibroblasts and immune cells,
into the developing CL (Tomac et al. 2011).
Several cytokines have been reported to play essential roles in luteogenesis. The most
characterized angiogenic regulators during the process are vascular endothelial growth factor
(VEGF) and fibroblast growth factor 2 (FGF2; Al-Zi’abi et al. 2003, Galvão et al. 2018). They are
both known to trigger the proliferation and migration of endothelial cells. Compared with VEGF,
FGF2 is a more potent stimulator of the proliferation of luteal endothelial cells (Zalman et al.
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2012), whereas VEGF also induces vascular permeability (Presta et al. 2005). The immunoneutralization of either VEGF-A (a member of the VEGF family) or FGF2 suppressed luteal
development and progesterone production in cows (Yamashita et al. 2008), and the inhibition of
VEGF-A completely prevented luteal vascularization and progesterone production in primates
(Wulff et al. 2001). A close temporal association between VEGF expression and angiogenesis in
the equine CL has also been demonstrated (Al-Zi’abi et al. 2003). Researchers suggest an
auto/paracrine effect, especially of tumor necrosis factor (TNF) and nitric oxide (NO), is present
to stimulate angiogenesis and progesterone secretion in early equine CL (Ferreira-Dias &
Skarzynski 2008, Ferreira-Dias et al. 2011, Galvão et al. 2012). In transitional mares, VEGF is
sparsely present in the anovulatory follicles, which likely explains the steroidogenic incompetence
of those follicles (Watson & Al-Zi’abi 2002). Also, the relative lack of vascular endothelial growth
factor receptor-2 (VEGFR-2) may affect the pro-angiogenic activity of VEGF-A and attribute to
the formation of the HAF in mares, despite the presence of physiological levels of VEGF-A
(Ellenberger et al. 2009).
The development of the CL is also accompanied by extensive remodeling of the ECM. The
ECM has a profound effect on cellular functions and has an integral part in the processes of
follicular development and atresia, ovulation, and the maintenance and regression of the CL. For
example, matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) have been
associated with substantial ECM remodeling for the occurrence of ovulation and CL establishment
(Sessions et al. 2009).
1.2.2. Maintenance of Corpus Luteum during Equine Pregnancy
During early equine pregnancy, the embryo migrates within the uterine lumen between
days 9 to 15 (Leith & Ginther 1984). This event leads to the maternal recognition of pregnancy
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and prevents the release of PGF2α by the endometrium, thus resulting in maintenance of pregnancy
(Zavy et al. 1984, McDowell et al. 1988). By preventing luteolysis, the CL is maintained and
continues to secrete progesterone. The CL formed after ovulation that results in pregnancy is called
the primary CL of pregnancy and actively secretes progesterone to support the early developing
pregnancy.
By approximately day 30 of gestation, progesterone production from the primary CL
decreases, resulting in significantly lower blood progesterone concentrations than the initial four
weeks (Van Rensburg & Van Niekerk 1968). In a normal pregnancy, blood progesterone
concentrations as low as 2.5 ng/mL can even be seen at this stage (Kelleman 2013). Meanwhile,
the unique structures known as the endometrial cups begin to form on the endometrial surface of
the pregnant mare by approximately day 36 after ovulation (Allen & Moor 1972). The cells that
form the basis of the endometrial cups are derived from the embryo, speciﬁcally from the chorionic
girdle comprised of specialized trophoblast cells. The endometrial cup cells produce eCG,
formerly known as pregnant mare’s serum gonadotropin (PMSG). This gonadotropic hormone first
appears in maternal blood days 37 to 40 after ovulation (Allen 1969). The endometrial cups
become mature and robustly secret eCG at approximately days 50 to 60, and then progressively
decline eCG secretion as sloughing of the endometrial cups occurs by days 100 to 150 of gestation.
The increased level of eCG stimulates follicular development in ovaries, which is followed by
either ovulation (with subsequent development of secondary CL) or luteinization without ovulation
(with subsequent development of accessory CL) of follicles (Squires et al. 1974, Ginther 1990).
All these new luteal structures, collectively called supplementary CLs, are thus produced and result
in a rise in the systemic concentration of progesterone. The primary CL is also stimulated by eCG;
therefore, it remains active, and its progesterone secretion is boosted (Squires & Ginther 1975).
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Progesterone from ovarian sources is vitally required for early pregnancy maintenance until
approximately day 45 of gestation. If pregnant mares are ovariectomized between days 50 to 70,
about 50% of them will abort (Holtan et al. 1979). This is the time when the fetoplacental unit
begins to produce progestagens and takes over the role of pregnancy maintenance. The CLs (both
primary and supplementary) continue to produce large quantities of progesterone, with high
systemic concentrations peaking at approximately days 60 to 120 of gestation. They are active
until regression begins at approximately days 150 to 180 after ovulation (Holtan et al. 1975).
Actual concentrations of blood progesterone are quite low in the pregnant mare after
approximately day 180 of gestation. By this time, the fetoplacental unit has taken over the
production of all progestagens by producing the reduced metabolites of pregnenolone and
progesterone, collectively known as 5α-reduced pregnanes, to continuously support the pregnancy
(Holtan et al. 1991). All ovarian luteal structures regress by approximately day 200 of gestation
(Discafani et al. 1995). Consequently, the quiescence of the equine uterus is believed to be
maintained during mid to late gestation by progestagens (Ousey et al. 2003).
1.2.3. Luteolysis: Regression of Corpus Luteum
Luteolysis occurs in the absence of pregnancy, followed by the return of estrus in
reproductively cycling animals. In non-pregnant mares, diestrus ends when the CL function,
i.e., progesterone secretion, ceases owing to the luteolytic action of pulsatile PGF2α secreted from
the endometrium on days 14 to 16 after ovulation. The pulsatile PGF2α secretions result in
functional and structural regression of the CL. Since the main metabolite of PGF2α, 13,14-dihydro15-keto prostaglandin F2α (PGFM), has a longer half-life in peripheral circulation than PGF2α, it
has been commonly applied as a useful analytical marker of PGF2α (Ginther et al. 2007b).
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Luteolysis in mares have several characteristic features. Firstly, pulses of PGFM lead to a
progressive decrease in serum concentrations of progesterone to basal levels in mares. This
contrasts with the fluctuation of progesterone level following PGFM pulses during the process of
luteolysis in cows (Ginther & Beg 2012). Secondly, PGF2α travels from the uterus to the ovaries
through systemic circulation in mares (Ginther 1998), whereas PGF2α is delivered from the uterine
horn locally to the adjacent ovary in cows (Ginther 1981). This general distribution of PGF2α in
the mare’s body is compensated by the slow clearance of PGF2α (Shrestha et al. 2012), and the
high luteal affinity to PGF2α (Kimball & Wyngarden 1977, Mattioli et al. 1983). However, the
high sensitivity to circulatory PGF2α predisposes mares to side effects associated with the
commonly used bolus injection of PGF2α, including sweating, colic-like signs, restlessness.
Furthermore, an auto-amplification of PGF2α has been proposed during luteolysis in
endometrial and luteal tissues in mares (Beg et al. 2005, Kozai et al. 2016), wherein PGF2α has a
positive effect on its own production. However, one study suggested that auto-amplification may
not be necessary for the induced luteolysis. (Ginther et al. 2019). Mares could still achieve
complete luteolysis by exogenous PGF2α when the endogenous secretion of PGF2α was presumably
suppressed by administering an inhibitor of the rate-limiting enzyme of PGF2α production (flunixin
meglumine). Lastly, no apparent alteration in luteal blood flow was observed before the decrease
in progesterone; however, it decreases after the peak of the PGFM pulse during spontaneous
luteolysis in mares (Ginther et al. 2007c, Ginther et al. 2008). Structural regression is characterized
by immune cell infiltration and different pathways of cell deaths of luteal cells (Al-Zi’abi et al.
2002, Ferreira‐Dias et al. 2007). The corpus albicans forms after the completion of structural
regression of the CL.
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Most studies of luteolysis in the literature used a single luteolytic bolus injection of PGF2α;
however, this injection also induces non-physiological events (Ginther 2012). For example, it has
been reported that a single luteolytic dose of PGF2α resulted in an immediate transient increase in
circulating progesterone and gonadotropins, which was not observed in the spontaneous luteolysis
in mares (Ginther & Beg 2009). These phenomena caused by the bolus injection may be elicited
by the above-mentioned auto-amplification mechanism upon the supraphysiological dose of
PGF2α. However, the significance of these phenomena remains to be elucidated.
1.3. Effect of Prostaglandin F2α on the Early Developing Corpus Luteum
1.3.1. Acquisition of Luteolytic Capacity
Different mechanisms among domestic animals control the functional lifespan of the CL
and the systemic level of its secretory product progesterone, which regulates the reproductive
cyclicity and supports the pregnancy (Bazer 2013, Klein 2016a). The identiﬁcation of PGF2α as
the endogenous luteolytic agent and the characterization of its luteolytic effects, when
administered exogenously, were reported in the 1970s (Ginther 1971, Douglas & Ginther 1972,
1976). Despite many studies performed in the past 50 years, the molecular mechanism of luteolysis
sensitivity acquisition in CL remains poorly understood. There is a prevailing assumption that the
CL is not responsive to the luteolytic effects of PGF2α before acquiring its luteolytic capacity,
i.e., there is a refractory period. However, it has been shown in many species that the receptor of
PGF2α (FP receptor) is present before the acquisition of luteolytic capacity. A summary of the
earliest day in the reproductive cycle in which the animal effectively responds to the luteolytic
treatment with a single injection in domestic species is listed in Table 1.1. Among the species listed
in Table 1.1, the sensitivity to PGF2α varies widely. It has been reported as early as day 3 after
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Table 1.1. Summary of the earliest days of effective luteolytic treatment with a single injection and identification of FP receptor in the
corpus luteum in different domestic species.
Species Earliest Day of Effective
Luteolytic Treatment
Rate of
Earliest Day of FP Receptor
#
Luteolytic Treatment
Complete
Presented in the Corpus
Luteolysis*
Luteum#
Equine
Horse: day 4.6 to 5
a: 37.5 μg d-cloprostenol, SC, day 4.6
a: 80% (16/20)
Day 4
a: Cuervo‐Arango &
b: 10 mg, PGF2α, SC, day 5
b: 100% (5/5)
(Vernon et al. 1979)
Newcombe 2012
b: Oxender et al. 1975

Bovine

Donkey: day 3
a: Carluccio et al. 2006
b: Carluccio et al. 2008

a,b: 75 μg, d-cloprostenol, IM

a: 100% (10/10)
b: 95% (21/22)

N/A

Day 5 to 5.5
a: Wenzinger & Bleul 2012
b: Valldecabres-Torres et
al. 2012

a: 15 mg, luprostiol, IM, day 5
b: 300 μg, d-cloprostenol, IM, day 5.5

a: 62.5% (5/8)
b: 80% (4/5)

Day 2
(Wiltbank et al. 1995)

a: 20 mg, PGF2α, IM
b: 1 mg, ICI-79339, IM

a: 100% (3/3)
b: 100% (2/2)

Day 6; day 0 = first day of
estrus
(Gadsby et al. 1990)

Porcine Day 12; day 0 = first day of
estrus
a: Connor et al. 1976
b: Guthrie & Polge 1976
#

Day 0 = ovulation, unless otherwise specified in the table.
*Complete luteolysis refers to the decrease in progesterone levels after treatment (<1.0 ng/mL) and no resurgence in luteal function before the subsequent
ovulation, or the expedited return to estrus after treatment when compared with control animals.
Abbreviation: N/A: not available, CL: corpus luteum, PGF2α: prostaglandin F2α, IM: intramuscularly, SC: subcutaneously.
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ovulation in the jenny and as late as day 12 after the first day of standing estrus in the sow.
Researchers believe the reported lack of responsiveness to the administration of PGF2α in the early
developing CL is not attributable to a deficiency of the FP receptor. Relatively recent studies
suggest that the early developing CL of mares is actually responsive to luteolytic effects of PGF2α
(Rubio et al. 2008, Cuervo‐Arango & Newcombe 2012, Coffman et al. 2014). Partial or complete
luteolysis can be achieved in the early developing CL by adjusting the protocols,
i.e., dosage, timing, frequency (Pinto & Coffman 2015, Coffman & Pinto 2016). The prevention
of luteal formation and the resulting low progesterone environment can be consistently induced
between two consecutive ovulations, namely the aluteal cycle.
1.3.2. Equine
In horses, the general concept is that the CL is not responsive to a single injection of PGF2α
until day 5 after ovulation, although it has been reported that a single injection of 10 mg of
dinoprost (the naturally occurring PGF2α) or 75 µg of cloprostenol (a synthetic PGF2α analog) on
day 3 after ovulation has induced complete luteolysis in some mares (Oxender et al. 1975, Bergfelt
et al. 2006, Tosi et al. 2008). The similar response was also observed when mares received two
consecutive daily injections of 100 to 600 µg of ICI-79939 (another synthetic PGF2α analog)
starting on day 3 or 4 after ovulation (Allen & Rowson 1973), three consecutive daily injections
of 2.5 mg of dinoprost starting on day 2 (Holland & Pinto 2008, Rubio et al. 2008), or twice daily
injections of 10 mg of dinoprost on days 0, 1, and 2 (Rubio et al. 2008).
The identification of FP receptors in the ovary of mares using immunoblotting and
immunostaining has only been reported in preovulatory follicles (Sayasith et al. 2006). Before
ovulation, the presence of the FP receptor has been shown in granulosa and theca cells of the
preovulatory follicle. The level of FP protein in preovulatory follicles was highly increased 33
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hours after injection of the ovulation-inducing agent, human chorionic gonadotropin (hCG). For
the CL, the PGF2α-specific binding assay performed in three studies suggested the presence of FP
receptor at various stages of diestrus (around days 4 to 16 after ovulation) in mares (Kimball &
Wyngarden 1977, Vernon et al. 1979, Mattioli et al. 1983). Nonetheless, the binding capacity to
PGF2α was lower in the 4-day-old CL when compared with the CL collected in mid-diestrus
(Vernon et al. 1979). Besides, another study showed that the addition of PGF2α into the culture
medium with luteal cells harvested from the 4- or 5-day-old CL tended to decrease the
progesterone secretion by the cells compared with the control (Watson 1991). These studies
indicated that the FP receptor is likely present in the early developing CL in mares, and the luteal
cells are potentially responsive to PGF2α. In the literature, several studies have shown that
exogenous luteolytic treatment caused a decrease or a delay in the rise of peripheral progesterone
concentration in mares with a CL less than five days old, which further provided the indirect
evidence that FP receptor is present in the early CL. A summary of studies on luteolytic or
antiluteogenic treatment effects on the early developing CL in mares (< five days after ovulation)
is listed in Table 1.2, arranged in an ascending order of dose of PGF2α or its analog used in the
studies.
Because of the rising concerns about luteal insufficiency in early equine pregnancy,
researchers started to investigate the effect of luteolytic agents on the blood concentration of
progesterone during the early period after ovulation. The first study had investigated the effect of
the administration of 10 mg of dinoprost (the naturally occurring PGF2α) once daily starting on the
day of ovulation (detected by transrectal palpation) for two consecutive days (Paccamonti et al.
1991). Plasma concentrations of progesterone were not altered in the treated mares in that study.
It is noteworthy that the least-squares mean concentration of plasma progesterone measured on
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Table 1.2. Summary of studies on the effects of administration of prostaglandin F2α on the early developing corpus luteum (< five days
old) in mares.
Drugs
Dose and
Duration* Frequency
Effect on Systemic Concentration of
References
Route
Progesterone/Progestins*
Dinoprost
1 mg, IM
Day 2
Once
Mares had a lower increase of plasma
Ferreira et al.
(PGF2α)
concentration of progesterone until
2018
48 hours after treatment and reduced
maximum plasma concentrations of
progesterone on days 8 to 11 when compared
with control groups (n=7).
2.5 mg, IM

Days 0-2

Twice daily

The treatment markedly suppressed the rise
in plasma progesterone in all treated mares,
followed by a resurgence in luteal function
(progesterone > 1.0 ng/mL). Six of seven
mares ovulated 14-26 days after treatment,
and one remained anovulatory.

Rubio et al.
2008

2.5 mg, IM

Days 0-2

Twice daily

All mares (n=10) within the 24 hours after
ovulation had circulating concentrations of
plasma progesterone suppressed during the
treatments but experienced a resurgence in
luteal function once treatments were stopped.

Pinto et al.
2014

2.5 mg, IM

Days 2-4

Once daily

Six of ten mares underwent complete
luteolysis and ovulated 9.4 ± 1.4 days; the
remaining four mares underwent partial
luteolysis, followed by a resurgence in luteal
function (progesterone > 1.0 ng/mL), and
ovulated 14.7 ± 2.1 days following treatment.

Rubio et al.
2008

(table cont’d.)
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Drugs
Dinoprost
(PGF2α)

Dose and
Route
2.5 mg, IM

Duration*

Frequency

Effect on Systemic Concentration of
Progesterone/Progestins*
Six of ten mares underwent complete
luteolysis 3.3 ± 0.2 days after the beginning
of treatment on day 2 after ovulation and
ovulated 9.4 ± 1.36 days after treatment. The
remaining four mares underwent partial
luteolysis followed by a resurgence in
circulating concentrations of plasma
progesterone. Three of these mares ovulated
with high progesterone levels on days 9, 15,
and 16 following treatments, respectively,
whereas the remaining mare underwent
natural luteolysis 16 days after treatment with
its ovulation occurring on day 19 following
treatment.

References

Days 2-4

Once daily

5 mg, IM

Days 0-2

Once daily

A decrease in plasma progesterone was
observed on day 4 during the first 14 days of
diestrus (n=13).

Mocklin et al.
2006

5 mg, IM

Days 0-2

Once daily

A decrease in plasma progesterone was
observed on days 2, 3, and 5 (n=10).

Brendemuehl
2000

10 mg, IM

Days 0-2

Once daily

No effects on the concentration of plasma
Paccamonti et
progesterone were noted on days 0 to 8 (n=6). al. 1991

10 mg, IM

Days 0-2

Twice daily

The mean plasma progesterone on day 5
remained <1.0 ng/mL, and four of six mares
ovulated 7.0 ± 1.8 days after treatment (n=6).

(table cont’d.)

14

Holland &
Pinto 2008

Rubio et al.
2008

Drugs
Dinoprost
(PGF2α)

Dose and
Route
10 mg, IM

Duration*

Frequency

Effect on Systemic Concentration of
Progesterone/Progestins*
Six of ten mares had complete suppression of
luteal function.

References

Days 0-2

Twice daily

10 mg, SC

Day 1

Once

No mares returned to estrus within ten days
after treatment (n=5).

Oxender et al.
1975

10 mg, IM

Day 2

Once

Mares had a lower increase of plasma
concentration of progesterone until
48 hours after treatment and reduced
maximum plasma concentrations of
progesterone on days 8 to 11 compared with
control groups (n=7).

Ferreira et al.
2018

10 mg, SC

Day 3

Once

Two of five mares had luteolysis on day 3
and return to estrus within ten days.

Oxender et al.
1975

10 mg, IM

Day 3

Once

A decrease in plasma progesterone was
Bergfelt et al.
observed on days 1-2 after treatment (n=16). 2006
A resurgence of the CL function was detected
in 75% (12/16) of the mares beginning three
days after treatment.

10 mg, IM

Days 0-4

Once daily

The mean daily progesterone concentration
from ovulation to embryo collection (day 22
or 23) was 0.86 ± 0.58 ng/mL (n=8).

(table cont’d.)
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Pinto et al.
2014

Leisinger 2018

Drugs
Dinoprost
(PGF2α)

Cloprostenol

Dose and
Route
10 mg, IM

Duration*

Frequency

Effect on Systemic Concentration of
Progesterone/Progestins*
All mares (n=10) had suppression of
the luteal function and earlier return to estrus
compared to the control cycles. Nine of ten
mares became pregnant when artificially
inseminated during the estrus after treatment.

Days 0-4

Twice daily for
the first three
days, once daily
for the following
two days

10 mg, IM

Days 0-4

Twice daily for
the first three
days, once daily
for the following
two days

The mean daily concentration of plasma
DiMiceli et al.
progesterone remained <1.0 ng/mL
2015
throughout all interovulatory intervals for two
consecutive cycles (n=4).

10 mg, IM

Days 0-4

Twice daily for
the first three
days, once daily
for the following
two days

The mean daily concentration of plasma
progesterone remained <1.0 ng/mL
throughout the study period (day 8) in the
aluteal group (n=7).

Leisinger et al.
2018

15 mg, SC

Days 2-4
(day 0 =
end of
estrus)

Once between
these three days

All treated mares showed no decrease in
plasma progesterone levels for the following
three days after treatment (n=3).

Kenney et al.
1975

25 µg, IM

Day 0, 1,
or 2

Once on the
Treated mares had progesterone
assigned treatment concentrations similar to control cycles
day
throughout the diestrous period (n=5 for each
group).

(table cont’d.)
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References
Coffman et al.
2014

Nie et al. 2003a

Drugs
Cloprostenol

Dose and
Route
25 µg, IM

Duration*

Frequency

Effect on Systemic Concentration of
Progesterone/Progestins*
For mares treated on day 2, Clo2x-D2 mares
had the lowest progesterone concentration on
days 3-7 and 13 after ovulation. The other
two treatment groups had progesterone
concentrations similar to control cycles
throughout the diestrous period (n=5 for each
group).

References

Day 0, 1,
or 2

Every 12 hours on
the assigned
treatment day

75 µg,
unspecified

Day 3

Once

Ten of 19 mares experienced complete
luteolysis (plasma progesterone <1.0 ng/mL);
nine of 19 mares had a slight decrease two to
three days after treatment, followed by a
resurgence in plasma progesterone.

Tosi et al. 2008

125 µg, IM

Days 0-3

Once daily

A reduction of progestin concentration from
Beyer et al.
the day of ovulation until day 14; progestin
2019
concentration on day 8 was 16.8 ± 3.9 ng/mL,
compared with 23.3 ± 2.0 ng/mL in control
group (n=8).

125 µg, IM

Days 0-3

Once daily

Decreased plasma progestin concentrations
were observed until day 34 (n=6).

Okada et al.
2020a

250 µg, IM

Day 0

Twice daily

A decrease in plasma progesterone was
observed on days 0, 1, 2, 3, and 5 after
ovulation (n=10).

Brendemuehl
2000

(table cont’d.)
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Nie et al. 2003a

Drugs
Cloprostenol

Dose and
Route
250 µg, IM

Duration*

Effect on Systemic Concentration of
Progesterone/Progestins*
Once on the
Progesterone concentrations in control mares
assigned treatment were significantly higher than levels in all
day
three treatment groups on days 3-7 (n=5 for
each group).

References

250 µg, IM

Day 0, 1,
or 2

Once on the
Mean progesterone concentrations observed
assigned treatment during control cycles were greater than
day
Clo-D1 and Clo-D2 cycles on day 3, and
Clo-D2 cycle on day 4, respectively. The
Clo-D0 group had progesterone
concentrations similar to control cycles
throughout the diestrous period (n=5 for each
group).

Nie et al. 2003a

250 µg, IM

Days 0-1

Once daily

Mares receiving treatment had significantly
lower progesterone concentrations on days 17 but not on days 8-14 (n=8).

Brendemuehl
2002

250 µg, IM

4 hours
Once daily
after
breeding to
2 days after
ovulation

Luteal function was impaired for several days
following treatment (days 2-9), but not on
days 11-15 (n=19).

Nie et al. 2003b

250 µg, IM

Days 0-2

Once daily

A decrease in plasma progesterone was
observed on days 4, 6, 8, and 10 during the
first 14 days of diestrus (n=11).

Mocklin et al.
2006

250 µg, IM

Days 0-2

Once daily

A decrease in plasma progesterone was
observed on days 2, 3, and 5 (n=10).

Brendemuehl
2000

Day 0, 1,
or 2

Frequency

(table cont’d.)
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Gunthle et al.
2000

Drugs
Cloprostenol

D-cloprostenol

Dose and
Route
250 µg, SC

Duration*

Frequency

Effect on Systemic Concentration of
Progesterone (Progestins)*
Some treated mares underwent complete
luteolysis at 80 (0%; 0/5), 88 (17.6%; 3/17),
96 (30.8%; 4/13), 104 (50%; 4/8), and 112
(75%; 3/4) hours after ovulation,
respectively.

References

Within
days 3.3
and 4.6
(88-112
hours)

Once on the
assigned hour

500 µg, IM

Days 0-2

Once daily

A decrease in plasma progesterone was found
on days 2 and 5 but not on day 8 or day 14
(n=8).

Troedsson et al.
2001

500 µg, SC

Within
days 3.3
and 4.6
(88-112
hours)

Once on the
assigned hour

Some treated mares underwent complete
luteolysis at 80 (16.7%; 3/18), 88 (36%;
18/50), 96 (65.2%;15/23), 104 (100%; 4/4),
and 112 (100%; 4/4) hours after ovulation,
respectively.

Cuervo‐Arango
& Newcombe
2012

750 µg, SC

Within
days 3.3
and 4.6
(88-112
hours)

Once on the
assigned hour

Some treated mares underwent complete
luteolysis at 80 (20%; 1/5), 88 (40%; 4/10),
96 (66.7%; 12/18), 104 (100%; 7/7), and 112
(100%; 3/3) hours after ovulation,
respectively.

Cuervo‐Arango
& Newcombe
2012

37.5 µg, SC

Within
days 3.3
and 4.6
(88-112
hours)

Once on the
assigned hour

Some treated mares underwent complete
luteolysis at 80 (5.2%; 1/19), 88 (23.1%;
3/13), 96 (26.1%; 6/23), 104 (53.3%; 16/30),
and 112 (80%; 16/20) hours after ovulation,
respectively.

Cuervo‐Arango
& Newcombe
2012

(table cont’d.)
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Cuervo‐Arango
& Newcombe
2012

Drugs
D-cloprostenol

ICI-79939

Dose and
Route
37.5 µg, IM

Duration*

Frequency

Within
days 3.3
and 4.6
(88-112
hours)

Once on the
assigned hour

Effect on Systemic Concentration of
Progesterone (Progestins)*
i) Some treated mares with single ovulation
underwent complete luteolysis at 88 (17.4%;
16/92), 96 (13.6%; 12/88), 104 (35.3%;
47/132), and 112 (66.1%; 72/108) hours after
ovulation, respectively.
ii) Some treated mares with asynchronous
double ovulations underwent complete
luteolysis at 88 (14.3%; 1/7), 96 (36.8%;
7/19), 104 (66.7%; 12/18), and 112 (80.0%;
12/15) hours after ovulation, respectively.
iii) Some treated mares with single ovulation
and intravaginal insertion of CIDR underwent
complete luteolysis at 88 (12.0%; 3/25), 96
(63.6%; 21/33), and 104 (68.4%; 13/19)
hours after ovulation, respectively.

References
Garcia‐Muñoz
et al. 2017

100-600 µg, Days 2-3
IM

Once daily

No treated mares returned to estrus within
four days of first treatment (n=4).

Allen &
Rowson 1973

100-600 µg, Days 3-4
IM

Once daily

Three of five treated mares returned to estrus
within four days of first treatment.

Allen &
Rowson 1973

100-600 µg, Days 4-5
IM

Once daily

All mares returned to estrus within four days
of first treatment (n=3).

Allen &
Rowson 1973

*

Day 0 = ovulation, unless otherwise specified in the table.
Abbreviation: CL: corpus luteum, PGF2α: prostaglandin F2α, IM: intramuscularly, SC: subcutaneously, CIDR: Controlled internal drug release device containing
1.38 g of progesterone, Eazi-Breed CIDR, UK.

(table cont’d.)
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day 0 ranged from 1.5 to 3.1 ng/mL. Therefore, the treatment might have been started on day 1 or
2 after ovulation instead of the day of ovulation (day 0). Later studies utilized a similar design, and
the day of ovulation was detected by using transrectal ultrasonography (Brendemuehl 2000,
Gunthle et al. 2000, Troedsson et al. 2001). These studies indicated that either single or multiple
injections of PGF2α or its analog at days 0, 1, and 2 had a detrimental effect on the luteal function
temporarily. For example, a temporary decrease in plasma progesterone in the treated mares was
noticed on day 5 but not on day 8 or 14 compared with the control mares in one study (Troedsson
et al. 2001), which might contribute to a lower pregnancy rate examined on day 14. In another
study, mares were administered with 250 µg of cloprostenol on days 0 and 1 once daily. The treated
mares also showed the temporary decreased luteal function in the treated mares, and the resurgence
of luteal function was noted on day 8 (Brendemuehl 2002). This intriguing phenomenon was
further investigated by the dual studies with a variety of treatment protocols (Nie et al. 2003a, b).
Researchers performed two studies with treating the mares with 250 µg of cloprostenol every 24
hours starting from four hours after insemination and continued through two days after ovulation
or treating mares with different doses of cloprostenol (25 or 250 µg) on a different day (day 0, 1,
or 2 after ovulation) with different frequencies (every 12 hours or once daily). The luteal function
appeared to be impaired by day 2 but seemed to rebound by day 9. In one of these two studies (Nie
et al. 2003b), the lower progesterone levels did not result in decreased pregnancies on day 15, in
contrast with a previous study (Troedsson et al. 2001).
Since there were contradictive results between studies using cloprostenol (the synthetic
analog of PGF2α) and dinoprost (the naturally occurring PGF2α), a study was performed to compare
the effect of administrating these two drugs in early diestrus, once daily on days 0, 1, and 2 after
ovulation, on the luteal function in mares (Mocklin et al. 2006). The authors found that both
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dinoprost and cloprostenol decreased plasma progesterone concentration at least temporarily
during diestrus. The effects of compromised luteal function on equine pregnancy have been
recently investigated, in which altered endometrial function and histotroph composition and
impaired conceptus development before placentation were found when the blood concentrations
of progestins had been experimentally reduced in the treated mares (Beyer et al. 2019, Okada et
al. 2020b).
As discovered in the early study (Oxender et al. 1975), some mares (two of five treated
mares) could achieve complete luteolysis, i.e., return to estrus, when they received a single
injection of PGF2α three days after ovulation. This finding has eventually been revisited after three
decades (Bergfelt et al. 2006). Similarly, although mares received a single intramuscular injection
of 10 mg of dinoprost on day 3 after ovulation responded with a precipitous decrease in the
concentration of plasma progesterone, only 25% of the treated mares (4/16) achieved complete
luteolysis. The rest of the treated mares (75%, 12/16) had a major or minor resurgence in luteal
function later in the estrous cycle (days 6 to 13). When mares were examined for detecting
ovulation more frequently (every 8 hours), a relatively effective response (80%, 16/20) of a single
luteolytic injection (d-cloprostenol) was observed when mares were treated at 112 hours (around
day 4.5) after ovulation (Cuervo‐Arango & Newcombe 2012). This response could even be more
effective (100%) and advanced to an earlier timing (104 hours) with using a higher dose of
d,l-cloprostenol. Surprisingly, the same research group also reported that the degree of complete
luteolysis could be influenced by increasing the concentration of progesterone during the early
luteal development in mares, either from the contribution of double ovulations or by insertion of
intravaginal progesterone device (CIDR) before injection (Garcia‐Muñoz et al. 2017). How the
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excess level of progesterone may influence the sensitivity to the luteolytic treatment in early
developing CL in mares requires further investigation.
Moreover, a series of experiments conducted in our laboratory produced data supporting
the hypothesis that the early developing CL is indeed responsive to exogenous PGF2α as early as
within the first 24 hours from ovulation and prevention of luteal formation could be accomplished.
This phenomenon was referred to PGF2α-induced “antiluteogenesis” and the induced cycle as
“aluteal cycle” because of this early luteolytic response to administration of PGF2α before the CL
is fully functional (Rubio et al. 2008, Coffman et al. 2014). This effect is dependent on the dose
and frequency of PGF2α treatments (Pinto & Coffman 2015). Some mares treated once or twice
daily for three days with 2.5 or 10 mg of PGF2α beginning at detected ovulation failed to show a
significant rise in plasma progesterone concentrations during the treatment period (Rubio et al.
2008). Approximately 60% of mares treated twice daily for three days with 10 mg of PGF2α
experienced complete antiluteogenesis. All mares receiving once daily 2.5 mg of PGF2α for three
days showed the resurgence of CL function. In a follow-up study, the addition of two doses on
days 3 and 4 following twice-daily administration on days 0 to 2 resulted in an antiluteogenic
response in all ten treated mares (Coffman et al. 2014). Therefore, it further supports the notion
that the antiluteogenic effect of serial administrations of PGF2α is dependent on the dose and
frequency of PGF2α treatments. Our laboratory has been using this treatment model to induce
aluteal cycles in mares, and all mares failed to show a significant rise in concentrations of plasma
progesterone in the treated cycles (Coffman et al. 2014, DiMiceli et al. 2015, Leisinger 2018). A
high pregnancy rate (90%, nine of ten) could be achieved in mares treated by the antiluteogenic
treatment (Coffman et al. 2014), and aluteal cycles could be induced in two consecutive cycles,
that is, three ovulation events were intercalated by two aluteal cycles (DiMiceli et al. 2015).
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Ultrasonographic, histopathological, and immunohistochemical examinations have been
performed on the early CLs on day 3 after ovulation from mares treated with antiluteogenic
treatment. A study reported that the CL was less distinguishable from the surrounding ovarian
tissue.The CL demonstrated signs of luteal regression, noted by the increased echogenicity of the
center surrounded by relatively hypoechoic tissue, decreased area of the CL (Coffman 2013). The
histopathological examination revealed the CL developed under the antiluteogenesis treatment had
decreased cellularity and organization, resulting in the appearance of interstitial hemorrhage and
moderate to severe parenchymal hemorrhage within the CL. There was a greater degree of
neutrophilic and eosinophilic infiltration into the parenchyma of the CL (Coffman 2013). The
cellular luteal regression in the CL collected on day 3 of the aluteal cycle was noted in the
histopathological examination of another study; however, the cellular change was not represented
in the immunohistochemical markers, i.e., steroidogenic acute regulatory protein (for
steroidogenesis), factor VIII (for angiogenesis) or caspase-3 (for apoptosis; Markle et al. 2018).
Additionally, the antiluteogenic treatment is not only applicable to the CL that arises from normal
ovulation. Our laboratory has also investigated its use in treating mares afflicted with
experimentally induced HAF (Davolli et al. 2018). Researchers have attempted to modify of the
“5-day protocol.” Mares still developed aluteal cycles when they were treated with 10 mg of PGF2α
once daily on days 0 through 4 (Leisinger et al. 2016), compared with the required twice-daily
injections for the first three days in the “5-day protocol.” Future studies on modifying the treatment
protocol to develop alternative protocols are warranted to reduce the frequency and duration of
treatment.
The early treatment with PGF2α has also been attempted in other equid species. In donkeys,
studies indicated that PGF2α treatment on day 3 after ovulation caused a functional regression of
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the CL in the treated jennies, reflected by the abrupt drop in circulating progesterone concentration
followed by the rapid return to estrus and ovulation. All ten jennies treated with
75 µg of d-cloprostenol intramuscularly on day 3 after ovulation attained complete luteolysis and
returned to estrus in one study (Carluccio et al. 2006). A follow-up study performed by the same
research groups reported that 21 of 22 treated jennies responded similarly. One treated jenny
responded to the d-cloprostenol injection on day 3 with an initial decrease in progesterone
concertation after treatment followed by a resurgence of CL function (Carluccio et al. 2008).
However, an inconsistent response to the PGF2α treatment on day 3 after ovulation has also been
reported when a different PGF2α analog, alfaprostol (3 mg, intramuscularly) was used (Panzani et
al. 2018). Only one of six treated jennies achieved complete luteolysis and ovulated eight days
after the treatment, while a partial luteolysis reflected by the resurgence in progesterone
concertation occurred in the other five treated jennies. Other researchers also reported that their
clinical experience seems to contradict the early response to PGF2α treatment in jennies (Canisso
et al. 2019). A controlled study of larger sample size is required to elucidate the earliest time-point
that jennies can respond to a single administration of PGF2α after ovulation.
1.3.3. Other Domestic Species: Bovine and Porcine
The bovine CL is also believed to be refractory to the luteolytic action of a single PGF 2α
injection before day 5 of the estrous cycle (day 0 = estrus; Lauderdale 1972, Tervit et al. 1973,
Henricks et al. 1974), despite the presence of FP receptors in early bovine CL (at least starting on
two days after ovulation, Table 1.1). The mechanism of refractoriness of the early bovine CL to
PGF2α has been deciphered by the incapability of inducing intraluteal synthesis of PGF2α (Tsai &
Wiltbank 1998), the lack of intraluteal vascular response to PGF2α injection (Acosta et al. 2002),
and the failure to upregulate mRNA expressions of many pathways related to luteolysis in the early
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CL (Mondal et al. 2011). Researchers have also investigated the effect of repeated administrations
of PGF2α on the early luteal function in cattle. When heifers were treated with two intramuscular
injections of 25 mg of PGF2α (dinoprost tromethamine) consecutively on days 3 and 4 of the estrous
cycle, the mean of estrous cycle length was significantly shortened to 6.2 days, compared to
18.3 days of the subsequent control cycle in the same group of heifers (Beal et al. 1980). Another
study showed that a persistently low progesterone environment after ovulation, similar to the
aluteal cycle reported in mares, could be induced in dairy cows in one study. (Kaneko & Takagi
2014). The cows received serial injections of 25 mg of PGF2α (dinoprost tromethamine)
intramuscularly daily for 21 days after natural ovulation. The mean serum concentration of
progesterone did not exceed 2 ng/mL over the 21-day sampling period. In the control cows, the
first dominant follicle that developed during diestrus became atretic without ovulation, and the
second dominant follicle ovulated between day 22 to 24 after the previous ovulation. In contrast,
nine of the 16 PGF2α-treated cows ovulated three dominant follicles consecutively during the 30day observation period. Other five PGF2α-treated cows ovulated two dominant follicles
consecutively, and the remaining two treated cows did not ovulate during the observation period.
The early developing CL started to regress approximately five days after each ovulation without
maturation in the PGF2α-treat cows. Both studies showed that bovine CL is responsive to the
luteolytic treatment before day 5 of the estrous cycle.
In pigs, most investigators consider the porcine CL refractory or insensitive to the luteolytic
effect of a single administration of PGF2α before day 12 of the estrous cycle (Diehl & Day 1974,
Hallford et al. 1975, Guthrie & Polge 1976, Lindloff et al. 1976). Similar to equine and bovine
CLs, one study has shown that the repeated administrations of PGF2α every 12 hours on
days 5 to 10 of the estrous cycle, was capable of inducing a premature luteal regression and a
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significant shortening of the estrous cycle length to approximately 13 days, compared with the
control group which was close to 20 days (Estill et al. 1993). Another study from the same
laboratory showed that cloprostenol was also effective in causing a significant reduction in the
length of the estrous cycle (13.5-15.2 days) when it was given once every 24 or 36 hours, i.e., total
of five and four injections, respectively, between days 6 and 10 of the estrous cycle (Gadsby et al.
1996). These two studies suggested the dosage-dependent luteolytic effect of PGF2α on the early
developing CL in pigs.
1.4. Progestagen Supplementation in Early Pregnant Mares
Progestagen is essential for the establishment and maintenance of pregnancy in mammals,
including horses. It is tempting to provide progestagen supplementation to breeding animals,
especially to mares that fail to conceive or carry a pregnancy to term. However, the widespread
use of progestagen supplementation in mares for preventing pregnancy failure is not evidencebased (Allen 2001, Fedorka & Troedsson 2021). It is often used as an empiric therapy on mares
that have a history of recurrent pregnancy loss without an identiﬁed cause. The focus of this section
is to review the use of progestagen in early pregnant mares aiming to support pregnancy.
For progestagen supplementation, the current options are natural progesterone and
synthetic progestins. Progestins are a group of synthetic steroid hormones that activate the
progesterone receptor in like manner as progesterone; however, only altrenogest was found to be
progestational in horses (McKinnon et al. 1993, McKinnon et al. 2000). The use of progestins
provides an advantage over progesterone for making a clinical decision. Since progesterone does
not cross-react with the most commonly used progestin, altrenogest, in commercial progesterone
assays (Wynn et al. 2018), the endogenous progesterone concentration can be monitored during
the period of supplementation in mares.
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The earlier study on the use of progestagen therapy of ovariectomized pregnant mares
provided the evidence that treatment with either progesterone-in-oil or oral altrenogest starting on
day 29 or 30 of gestation can support pregnancy at least up to day 100 in pregnant mares which
were ovariectomized on day 34 or 35 (Shideler et al. 1982). This study also provided the
information that has been widely applied in clinical practice and cited in the literature thereafter.
The systemic concentration of progesterone above 4.0 ng/mL is considered sufficient to support
pregnancy, whereas the pregnancy is considered at risk when the progesterone level is below
2.0 ng/mL. The use of exogenous progesterone-in-oil for establishing equine pregnancy without
an endogenous source of progesterone was further supported by multiple studies using
progesterone-treated ovariectomized embryo recipient mares (Hinrichs et al. 1985, Hinrichs et al.
1986, Hinrichs et al. 1987, McKinnon et al. 1988, Knowles et al. 1993). Other formulations of
progesterone have also been shown their effectiveness to maintain early pregnancy in mares (Ball
et al. 1992a, Vanderwall et al. 2007). Researchers found that progesterone supplementation in a
natural pregnancy did not affect the tubal transportation of the embryo, embryo recovery rate, or
early embryonic development in the first week of pregnancy in mares (Hinrichs & Watson 1991,
Ball et al. 1992b). Besides progesterone, the 5α-reduced metabolite of progesterone,
5α-dihydroprogesterone (DHP), has been recently suggested to be the second endogenous potent
progesterone receptor agonist in early equine pregnancy (Scholtz et al. 2014, Conley et al. 2018).
As a metabolite of progesterone, DHP is hypothesized to be synthesized peripherally from luteal
progesterone, and it is capable of supporting pregnancy in PGF2α-treated mares at least until day
27 after ovulation (Scholtz et al. 2014).
Among all the synthetic progestins investigated, altrenogest (also called allyltrenbolone or
allyltrienolone), is the only synthetic progestin being effective in supporting pregnancy in mares.
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Most mares treated with oral altrenogest starting on day 15 or 16 after ovulation (0.044 mg/kg,
orally, daily) could maintain pregnancy up to at least day 30 of gestation or until term following
either administration of PGF2α on day 18 of gestation or ovariectomy on day 17 (McKinnon et al.
1993, McKinnon et al. 2000). Researchers found that various other synthetic progestins failed to
maintain pregnancy in PGF2α-treated or ovariectomized mares administered with the following
progestins: hydroxyprogesterone caproate (500 mg, intramuscularly, every two or seven days),
medroxyprogesterone acetate (1000 mg, intramuscularly, every seven days), hydroxyprogesterone
hexanoate (500 mg, intramuscularly, every four days), norgestomet (15 mg, in the form of five
subcutaneous slow-release implants), and megestrol acetate (500 mg; orally, daily). No alteration
has been noted in the hematologic and biochemical parameters of mares that received oral
altrenogest for a long period (Shideler et al. 1983), although the enlarged clitoris in ﬁllies born to
mares treated with altrenogest in late gestation has been reported (Shoemaker et al. 1989). The
injectable form of altrenogest has been tested for safety and efficacy as well. In one safety study,
there were no significant differences in the physical and hematological examinations after mares
received the injection intramuscularly, while minor biochemical changes in muscle enzymes and
low incidence of injection site reactions were observed (McConaghy et al. 2016). Recent research
has focused on determining the efficacy of other routes and regimens of altrenogest treatment.
Although intrarectal and intravaginal administrations of altrenogest (0.044 mg/kg) resulted in
absorption into the systemic circulation in mares, concentrations of plasma altrenogest were
significantly lower than that after oral administration (Hornberger et al. 2019). Another study
suggested the “double dose” of altrenogest (0.088 mg/kg) given intrarectally with more frequent
administration (every four to eight hours) would be necessary to maintain therapeutic
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concentrations over 24 hours for pregnancy maintenance therapy in mares unable or unwilling to
receive oral altrenogest (Ellis et al. 2019).
In addition to preparing acyclic or ovariectomized mares as embryo recipients (Hinrichs et
al. 1986, McKinnon et al. , Lagneaux & Palmer 1993, Oliveira Neto et al. 2018), the use of
altrenogest in recipients could potentially increase donor-recipient synchrony (Parry-Weeks &
Holtan 1987). While researchers showed that the rate of pregnancy loss after embryo transfer
tended to be lower in the altrenogest-treated recipient mares when compared with the untreated
mares (Panzani et al. 2009), others suggested that high pregnancy rates could be achieved by
experienced operators using conventional embryo transfer technique and by less experienced
operators with Wilsher technique, in the absence of any supportive hormonal treatments (Stout
2006, Cuervo‐Arango et al. 2018). Based on the serial ultrasound examinations, studies showed
that the conceptus growth rate between days 10 and 50 of gestation was not affected by the
treatment with altrenogest in pregnant mares, with or without the support of luteal progesterone
(Voller et al. 1991, Willmann et al. 2011). However, the retarded development of the conceptus
between days 30 and 45 in older mares (> eight years) was improved by the treatment with
altrenogest in one study (Willmann et al. 2011). There are conflicting data in the literature on
whether altrenogest treatment would suppress endogenous progesterone production in mares
(Jackson et al. 1986, Parry-Weeks & Holtan 1987, Voller et al. 1991, Daels et al. 1992, DeLuca
et al. 2011, Beyer et al. 2019). In spite of that, altrenogest administration during pregnancy has
been reported to decrease the production of eCG in mares greater than eight years of age (Willmann
et al. 2011), and interfere the formation of secondary CL during pregnancy (Daels et al. 1992).
The administration of progestagen to mares with a history of early pregnancy loss has
become commonplace. Despite the convincing results indicating the supportive role of
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progestagen in early equine pregnancy, the necessity of applying progestagen therapy to mares
remains unclear since the prevalence of true luteal insufficiency is controversial (Irvine et al. 1990,
Allen 2001). However, there is no study looking at the effect of altrenogest on the establishment
of early equine pregnancy before seven days of gestation (tubal-stage embryo) since most studies
were performed on the embryo transfer model on ovariectomized mares at a later stage. Whether
exogenous progestagen alone can support the early embryonic development at that stage remains
to be elucidated. More importantly, a controlled study is warranted to study any potential beneficial
effect of supplementing progestagen to pregnant mares since the potential alteration of the mare’s
immune system by altrenogest has been proposed recently (Fedorka et al. 2019).
1.5. Future Direction
Studies among different domestic species indicated that the early developing CL is
responsive to PGF2α before the “refractory period.” Whether this phenomenon will lead to luteal
insufficiency and early pregnancy loss in breeding mares naturally remains to be investigated. The
PGF2α-induced aluteal cycle in mares can serve as a useful tool for researchers to understand the
role of progestagen in early equine pregnancy and to evaluate the necessity of the prophylactic use
of progestational supplementation in mares after breeding. It is seemingly that partial or complete
luteolysis can be achieved in the early developing CL by adjusting the protocols, i.e., dosage,
timing, frequency. Future studies are warranted to adjust the treatment regimen with PGF2α for
inducing an aluteal cycle in mares with a reduction in the number of injections required in the
currently available protocol.
Furthermore, the ability to prevent luteal function shortly after ovulation or hemorrhagic
anovulatory dysfunction may be critical to induce an early return to estrus or to treat HAF,
respectively. The antiluteogenic treatment protocol can be potentially used for hormonal
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manipulation of the estrous cycle in mares. Future studies are warranted to assess its efficacy and
effectiveness in clinical settings.
1.6. Scope of the Dissertation
The main objective of this dissertation research was to study the effect of endogenous and
exogenous progestagens on early embryonic development and reproductive parameters in the
subsequent estrus using an equine pregnancy model characterized by a progesterone-deprived
environment induced by serial administrations of PGF2α, namely aluteal model. Our first overall
hypothesis was that viable day 7 embryos could be collected from aluteal mares, denoting that
physiological progestagen levels may not be critical for early embryonic development during tubal
transport. Our second hypothesis was that the exogenous progestagen would support early equine
pregnancy in an aluteal environment since conception. Our last hypothesis was that an aluteal cycle
could be induced by a more frequent treatment regimen for a shorter duration when compared with
the current antiluteogenic protocol.
Specifically, the goals of the project were: 1) to perform a morphometric analysis of equine
embryo collected on day 7 in aluteal and aluteal-supplemented cycles; 2) to evaluate the early
embryonic development solely supported by long-acting injectable altrenogest until day 24 in
mares without the primary CL; 3) to investigate the reproductive hormonal profile in aluteal cycles
with or without altrenogest supplementation and characterized the reproductive parameters in the
subsequent estrus; 4) to investigate the luteal function after ovulation when mares were treated
with a constant-rate infusion of PGF2α.
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CHAPTER 2. CHARACTERIZATION OF DAY 7 AND DAY 24 EMBRYOS
IN ALUTEAL-SUPPLEMENTED CYCLES IN MARES
2.1. Introduction
Like many domestic species, progesterone is secreted by the corpus luteum (CL) following
ovulation in mares. Together with its 5α-reduced metabolite, 5α-dihydroprogesterone (Scholtz et
al. 2014, Conley et al. 2018), these two progestagens create a nurturing, receptive, and protective
uterine environment to support adequate embryonic development (Aurich & Budik 2015, Pinto
2020). The reciprocal signaling between the maternal environment and the developing embryo is
crucial for maintaining luteal function and the establishment of pregnancy. However, the
mechanism of maternal recognition of pregnancy in horses remains elusive (Klein & Troedsson
2011). Equine pregnancy has a relatively prolonged preimplantation period compared with other
domestic species. The embryo development is mainly supported by the secretion of progesteronestimulated endometrial glands, termed the histotroph (Allen & Wilsher 2009). Upon the embryo’s
entry into the uterus between 130 to 144 hours (5.5-6 days) after ovulation (Freeman et al. 1991),
an embryonic capsule is transiently formed between the trophectoderm and the overlying zona
pellucida (Stout et al. 2005), to protect the embryo during the mobile phase and also to facilitate
nutrient uptake, especially lipids, by the embryo (Allen & Wilsher 2009).
The fertilization rate is generally believed to be excellent in most horses (Ball et al. 1986,
Carnevale et al. 1993); however, the rate of embryonic loss in the first two to three weeks of
pregnancy can be extremely high in some subfertile populations (Ball 1988). Because in mares the
embryonic vesicle can be detected by transrectal ultrasonography as soon as the embryonic
diameter reaches ~ 2 mm (around days 9.5 to 10 of gestation), the incidence of embryonic loss
after that point can be recorded (Vanderwall 2008). Due to the lack of a reliable and minimally
invasive method to diagnose equine pregnancy earlier than day 10, the cause of embryonic loss
33

that occurs during the first ten days of gestation remains poorly investigated. The information on
early embryonic loss during that period is primarily derived from the difference between the
pregnancy rate at the first three days of gestation (recovering the embryo from the uterine tube
ipsilateral to ovulation) and that at day 11 or 14 as determined by transrectal ultrasonography (Ball
et al. 1986, Carnevale et al. 1993). The rate of embryonic loss before day 10 in mares has also
been estimated indirectly from the embryo recovery data on days 6 to 9 after ovulation (Vogelsang
& Vogelsang 1989), or from the discrepancy between numbers of detected embryonic vesicles and
the number of ovulated follicles (Morel et al. 2005). Due to the critical role of progesterone during
early equine pregnancy, luteal insufﬁciency has been frequently suspected as one of the potential
causes of early embryonic loss (Ginther et al. 1985, Bergfelt et al. 1992). Although the prevalence
of true luteal insufﬁciency in mares is controversial (Allen 2001, Staempfli 2015), researchers have
recently suggested that hypoluteoidism could be a more important cause for early embryonic loss
in mares than previously assumed (Betteridge et al. 2018). However, the therapeutic options for
early embryonic loss in mares are very limi0ted, especially for horse breeds not allowed to take
advantage of assisted reproductive techniques to produce registered foals. Mares with a history of
embryonic loss or subfertility are commonly supplemented with progestagens (progesterone or
synthetic progestins), even without any hormone measurement or ultrasound findings suggesting
primary luteal insufficiency. D0espite the widespread use of altrenogest in the equine breeding
industry, progestagen supplementation for preventing spontaneous embryonic loss in mares has
not yet been critically tested. To our best knowledge, the efficacy of using synthetic progestins,
e.g., altrenogest, to establish and maintain an early equine pregnancy (< seven days of age) under
a progesterone-deprived environment has not been investigated in horses.
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Our laboratory has developed an in vivo mare model, namely the aluteal pregnancy model,
in which mares are given serial injections of prostaglandin F2α (PGF2α) to induce a persistently low
progesterone environment characterized by failure of luteal formation (Leisinger et al. 2018). This
experimental model is useful for studying the effect of progesterone deprivation on the embryo
and endometrium because the progesterone level is much lower (<1.0 ng/mL) when compared
with those in other hypoluteal models in diestrual mares (Ferreira et al. 2018, Beyer et al. 2019).
Our laboratory has previously shown that the embryos developed in aluteal cycles were
developmentally retarded with poor embryo quality when collected on day 8 after ovulation
(Leisinger et al. 2018). Furthermore, endometrial biopsies collected on day 8 in aluteal cycles also
revealed dysregulation of important pregnancy-related genes, despite a potential compensatory
response detected in the embryo (Leisinger et al. 2019). Intriguingly, the equine pregnancy
developed under this aluteal condition could be “rescued” and maintained at least up to the
presence of embryonic heartbeat on day 22 or 23 by the supplementation of one single long-acting
injectable altrenogest on day 5 after ovulation, although a lower pregnant rate and delayed
embryonic growth were observed when compared with embryos collected from control, luteal
mares (Leisinger et al. 2016).
This study aimed to investigate the effects of both endogenous and exogenous progestagens
on early equine embryonic development and the endometrial environment on day 7 after ovulation,
and maintenance of pregnancy up to the presence of an embryonic heartbeat using the aluteal
pregnancy model. We hypothesized the degeneration of day 8 aluteal embryos described in the
previous study occurred after the entry of the embryo into the progesterone-deprived uterus;
therefore, the aluteal embryo collected from the uterus a day earlier, i.e., day 7 after ovulation,
would not deteriorate, despite a delay in the embryo developmental stage. We also hypothesized
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that progestagen supplementation (altrenogest) since ovulation would compensate for the adverse
environment in aluteal cycles on day 7 and support pregnancy until detection of an embryonic
heartbeat in mares.
2.2. Materials and Methods
2.2.1. Study Design
The two experiments in this study were approved by the Louisiana State University School
of Veterinary Medicine Institutional Animal Care and Use Committee. Both experiments were
performed at Louisiana State University in Baton Rouge, LA. The experimental animals were
handled following The Guide for the Care and Use of Laboratory Animals.
Experiment 1. Examination of Day 7 Equine Embryos in Aluteal-supplemented Cycles
This experiment was performed from May to November in 2018. Eight cyclic light breed
mares (Equus caballus) aged between five and ten years (mean ± SEM = 7.3 ± 0.6 years) were
included in this experiment. Mares were kept in large pastures with covered sheds. They were fed
grain twice daily, and water and grass hay were available ad libitum.
Mares were examined three times a week by transrectal ultrasonography (SonoSite Edge,
FUJIFILM SonoSite Inc., Bothell, WA) for monitoring of their estrous cycles. To induce
ovulation, estrous mares having a follicle ≥35 mm in diameter, with uterine edema observed via
ultrasonography, were treated once with 2000 IU of human chorionic gonadotropin intravenously
(hCG; Chorulon, Merck Animal Health, Kenilworth, NJ). Mares were artiﬁcially inseminated with
extended fresh semen containing ≥1 x 109 progressively motile spermatozoa from one stallion of
known fertility every other day until ovulation was detected. Transrectal ultrasonographic
examinations were performed twice daily (AM and PM) after insemination until detection of
ovulation (day 0). Upon ovulation, mares were randomly assigned to one of three groups: control
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luteal cycle (Ctrl), aluteal cycle (AL), or aluteal-supplemented cycle (AL-Suppl). Mares in AL and
AL-Suppl cycles were treated according to a previously described protocol (Coffman et al. 2014).
Briefly, they were treated intramuscularly with 10 mg of dinoprost tromethamine (a tromethamine
salt of the naturally occurring PGF2α, Lutalyse, Zoetis, Parsippany, NJ) immediately after the
detection of ovulation (day 0). Mares were treated with eight serial injections of PGF2α, twice daily
on days 0, 1, and 2, and once daily on days 3 and 4. Mares in Ctrl cycles were treated with the
same volume (2 mL) of saline solution intramuscularly on the same schedule. Mares in AL-Suppl
cycles were further treated with a single intramuscular injection of 225 mg of long-acting
altrenogest solution (BioRelease Altrenogest LA150, BET Pharm, Lexington, KY) on day 0 upon
detection of ovulation.
Embryo collections were performed on day 7 after ovulation in an aseptic manner using
lactated Ringer’s solution (LRS) with no supplementation (MWI Veterinary Supply, Boise, ID).
The cervical tone was evaluated by transrectal palpation and transvaginal digital palpation, which
were performed prior to uterine lavage and cervical catheterization, respectively. The cervical tone
was classified as poor, fair, and good as modified from previously reported grading systems
(Hinrichs et al. 1986, Day et al. 1995). Poor cervical tone was defined as a slightly open and flaccid
cervix indistinguishable from the uterus transrectally; fair cervical tone was defined as a slightly
closed and soft-firm cervix distinguishable from the uterus transrectally; good cervical tone was
defined as a closed and firm cervix distinguishable from the uterus transrectally. The uterus was
lavaged with 1 to 1.5 L of LRS at a time and an average of 4 to 6 L of LRS was used per collection.
After a successful embryo collection, endometrial biopsy samples were taken using alligator-type
biopsy forceps. The biopsy sample was immediately placed in a 1.2-mL cryogenic vial (VWR,
Radnor, PA), snap-frozen, and stored in liquid nitrogen until RNA isolation was performed. Mares
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were treated with 10 mg of PGF2α intramuscularly after embryo collection. Daily blood samples
were collected starting from the day of ovulation (day 0) until embryo collection (day 7) in all
three cycles. Plasma samples were harvested and stored at -20 °C until measurement for
progesterone.
Mares remained in the assigned group until a successful embryo collection. After a
successful embryo collection, they were assigned to another group. This randomized crossover
study was designed to collect embryos and endometrial samples from three different cycles in each
mare on day 7.
Experiment 2. Examination of Equine Pregnancy in Aluteal-supplemented Cycles until Day 24
The second experiment was performed in two breeding seasons in 2019 and 2020. Eight
cyclic light breed mares (Equus caballus) aged between three and 15 years (mean ± SEM = 8.4
± 1.4 years) were included. Before enrollment, a breeding soundness examination, including an
assessment of perineal conformation, uterine culture, cytology, and biopsy, was performed. Mares
were enrolled only if the following inclusion criteria were fulfilled: (1) the endometrial biopsy was
assigned a grade I or IIA using Kenney and Doig’s grading scheme for horses (Kenney & Doig
1986); (2) no growth on aerobic bacterial culture for two days; and (3) cytology results revealed
no evidence for inflammation. Mares were kept and fed in the same way as mentioned in
Experiment 1.
Mares were examined three times a week by transrectal ultrasonography (ExaPad and
ExaGo; IMV imaging, France) to monitor their estrous cycles. Estrous mares having a follicle
≥35 mm in diameter with uterine edema observed ultrasonographically, were treated once with
2000 IU of hCG intravenously for induction of ovulation. Mares were artiﬁcially inseminated with
extended fresh semen containing ≥1 x 109 progressively motile spermatozoa from one stallion of
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known fertility every other day until ovulation was detected. Transrectal ultrasonographic
examinations were performed twice daily (AM and PM) after insemination until detection of
ovulation (day 0) and three times a week until day 12 after ovulation. Upon ovulation, mares were
randomized into control cycle (Ctrl) or treatment cycle (AL-Suppl). For the treatment cycle, mares
were treated as described previously in Experiment 1 as in the aluteal-supplemented cycle. Mares
were treated with eight serial injections of PGF2α starting as soon as ovulation was detected, and
an additional injection of a long-acting altrenogest solution. For the control cycle, the same volume
of saline solution was substituted for the injections of PGF2α and altrenogest. Pregnancies were
confirmed by detecting embryonic vesicles via transrectal ultrasonography, on days 12, 15, 18, 21
and 24 after ovulation. No further pregnancy examinations were performed when no embryonic
vesicles were found on day 15. Whenever a pregnancy was detected, serial measurements of the
embryonic diameter were taken over the subsequent reproductive examinations. A second
administration of 225 mg of altrenogest (AL-Suppl) or saline solution (Ctrl) was given on day 12
if pregnancy was detected. Examination of the embryonic heartbeat was performed via transrectal
ultrasonography on day 21 and day 24 before terminating the pregnancy by uterine lavage. Mares
were treated with 10 mg of PGF2α intramuscularly immediately after embryo collection. Mares
were monitored for return to estrus by ultrasonography every other day after embryo collection or
the end of the first cycle for non-pregnant mares. In the subsequent cycle, each mare was assigned
into the opposite group for this crossover study. Daily blood samples were collected starting from
the day of ovulation (day 0) until embryo collection (day 24) in pregnant mares or day 12 for nonpregnant mares. Plasma samples were harvested and stored at -20 °C until assayed for progesterone
and altrenogest concentrations using radioimmunoassay (RIA) and liquid chromatography with
tandem mass spectrometry (LC-MS/MS), respectively.
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2.2.2. Evaluation of Day 7 Embryos
The rate of successful embryo collection for each group was calculated by dividing the
number of successful embryo collection procedures, i.e., collection of one or more embryos, by
the total number of embryos collection attempts. Day 7 equine embryos were evaluated using a
stereomicroscope (SMZ800, Nikon, Melville, NY). Embryos were classified into four categories
according to their development from early to late stage: morula, early blastocyst, blastocyst, and
expanded blastocyst (McCue & Squires 2015). The embryo quality was graded morphologically
from 1 to 4, with the lowest score being the best quality (McCue & Squires 2015). Embryos were
then photographed, and their diameters were measured using an inverted microscope (IX73,
Olympus, Tokyo, Japan) equipped with imaging software. To assess the embryo viability by the
percentage of dead blastomeres, embryos were stained with 1 µg/mL of 4’,6-diamidino-2phenylindole (DAPI; D9542, Sigma-Aldrich, St. Louis, MO) dissolved in a commercial embryo
holding medium (EmCare™ Holding Solution, ICP Bio, Spring Valley, WI) at room temperature
(approximately 23 °C) for 15 minutes (Huhtinen et al. 1997). The stained embryos were evaluated
using an inverted ﬂuorescent microscope (IX73, Olympus, Tokyo, Japan). Video clips of the
DAPI-stained embryos were recorded with a digital camera (Retiga R1, QImaging, Surrey,
Canada) and an imaging software (Ocular, QImaging, Surrey, Canada) for about ten seconds and
the cells were analyzed from video clips. Fluorescing cells were considered compromised and
nonviable. After that, embryos were fixed in 10% neutral buffered formalin for 24 hours and stored
in 70% ethanol for immunofluorescence staining.
2.2.3. Immunofluorescence Staining of Day 7 Embryos
Day 7 embryos stored in 70% ethanol were stained for immunofluorescence with
commercially available kit agents (MAXpack™ Immunostaining Media Kit, Active Motif,
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Carlsbad, CA), using mouse monoclonal antibody, OC-1, as a primary antibody against the equine
embryonic capsule (Oriol et al. 1993). Embryos were first washed three times for 15 minutes with
MAXwash™ Washing Medium at room temperature. After that, non-specific staining was blocked
by incubation in MAXblock™ Blocking Medium, for one hour at 37 °C. Embryos were then
washed again and incubated with the primary antibody (mouse monoclonal anti-capsule OC-1 in
1:100 dilution of MAXbind™ Staining Medium) for one hour at 37 °C. Negative controls
consisted of blastocysts incubated without the primary antibody, and oocytes incubated with the
primary antibody. After a washing step, incubation with the secondary antibody (Donkey antiMouse-Alexa Fluor® 555; A-31570, Invitrogen, Eugene, OR) in 1:300 dilution of MAXbind™
Staining Medium was performed for one hour at 37 °C, followed by another washing step.
Embryos were then mounted on a glass slide and nuclei were stained by ProLong™ Gold Antifade
Mountant with DAPI (P36931, Invitrogen, Eugene, OR). A glass coverslip was used to flatten the
embryo and the edges of the coverslip were then sealed with nail polish. All embryos were
evaluated in one session with identical settings using an upright fluorescent microscope (Eclipse
Ni-E, Nikon, Tokyo, Japan) with its accompanying software (NIS Elements AR, Nikon, Tokyo,
Japan). Images were saved, and the fluorescence intensity of the capsule was measured by imaging
software (ImageJ, NIH, Bethesda, MD, USA). For each embryo, the mean fluorescence intensity
of three different randomly selected areas of the capsule were measured and the mean of these
three measurements was calculated as previously described (Smits et al. 2012).
2.2.4. Progesterone Assay
In Experiment 1, daily plasma samples from day 0 (day of ovulation) to day 7 (day of
embryo collection) were collected. In Experiment 2, daily plasma samples were collected from
day 0 (day of ovulation) to day 12 (day of pregnancy diagnosis) for all mares, and every two days
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from day 14 to day 24 (day of embryo collection) for pregnant mares only. Frozen plasma samples
were thawed, and concentrations of plasma progesterone were determined by a progesterone
radioimmunoassay (RIA), using commercially available kit reagents (ImmuChem Double
Antibody,
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I RIA Kit, MP Biomedicals, Costa Mesa, CA), and the assay sensitivity was

0.05 ng/mL.
2.2.5. Altrenogest Assay
Selected paired plasma samples collected in Experiment 2 (day 2 and day 12 after the first
altrenogest injection from 4 mares) were measured for altrenogest concentrations by using liquid
chromatography with tandem mass spectrometry (LC-MS/MS) validated for equine plasma at the
Southern Alberta Mass Spectrometry Facility at University of Calgary. The analytical-graded
altrenogest (33994, Sigma-Aldrich, St Louis, Mo, USA) was used to develop the assay via the aid
of a deuterated internal standard, which was selected based on its structure and the retention time
of altrenogest on the system.
2.2.6. RNA Isolation from Day 7 Endometrial Samples
Total RNA was isolated from 50 to 100 mg of endometrial biopsy samples using TRIzol
reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s
instructions. The RNA was adjusted to a total volume of 100 μL and was precipitated using an
equal amount of isopropanol and 1/10 the amount of 3M sodium acetate followed by
centrifugation. The RNA pellet was washed using 75% ethanol and was resuspended in water. The
RNA concentration was assessed through the NanoDrop spectrophotometer (Thermo Fisher
Scientific), and samples with a 260/280 ratio close to 1.95, and a 260/230 ratio close to 2.0 were
used for further analysis.
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2.2.7. Real-time Reverse Transcription Polymerase Chain Reaction
A total of 1 µg of RNA was used as the template for cDNA synthesis reaction using the
High-Capacity Reverse Transcription Kit (Thermo Fisher Scientific). Eight transcripts were
chosen for evaluation in the endometrium samples: P19/uterocalin (P19), secretoglobin family 1A
member 1/uteroglobin (SCGB1A1), acid phosphatase 5/uteroferrin (ACP5), progesterone receptor
(PGR), estrogen receptor 1 (ESR1), hexokinase 2 (HK2), secretory phospholipase A2 (SPLA2),
and connective tissue growth factor (CTGF). Primers were designed using Primer-BLAST
(https://www.ncbi.nlm.nih.gov/tools/primer-blast); all products were less than 180 bp and are
listed in Table 2.1. Real-time reverse transcription polymerase chain reaction (RT-PCR) was
carried out in duplicate using the StepOnePlus™ Real-time PCR system (Thermo Fisher
Scientific) and SYBR™ Green PCR Master Mix (Thermo Fisher Scientific) with a total volume
of 10 μL containing 200 nM of forward and reverse primer and 1 μL of cDNA. A no-template
control and no reverse transcriptase control were included. The housekeeping genes used in this
study were glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-actin (ACTB) as both
genes are stable in equine endometrial tissue (Klein et al. 2011). Following the completion of RTPCR, the cycle number where the fluorescent signal intersected the threshold (Cq) was recorded.
To obtain ΔCq, replicates of Cq were averaged and normalized to the housekeeping genes by
subtracting the average Cq for GAPDH and ACTB from Cq for each sample. Fold changes relative
to Ctrl cycle were calculated using the ΔΔCq method.
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Table 2.1. List of primers used in real-time reverse transcription polymerase chain reaction.
Symbol
Gene Name
Protein Function
Accession Number Sequence 5’–>3’
GAPDH

ACTB

Glyceraldehyde-3phosphate
dehydrogenase

House-keeping gene

Beta-actin

House-keeping gene

NM_001163856.1

F: TTGTCAAGCTCATTTCCTGGTATG
R: GTTAGGGGGTCAAGTTGGGAC

NM_001081838.1

F: CGACATCCGTAAGGACCTGT
R: CAGGGCTGTGATCTCCTTCT

P19

P19/uterocalin

Lipophilic molecular NM_001082509.2
transporter

F: ATGAAGCACGGGAAGGAGAC
R: ACATCCACATGACATCCGGG

SCGB1A1

ACP5

PGR

Secretoglobin
family 1A member
1/uteroglobin

Anti-inflammatory

Acid phosphatase
5/uteroferrin

Phosphate
hydrolysis in
osteonectin function

XM_023644136.1

Hormonal activity

XM_001498494.4

Progesterone
receptor

XM_023653827.1

F: AGAAGGCATCTCAATACGCACA
R: GGGTGCTCATCATGGCGAGT
F: CTGGGAACTTCATGGACCCC
R: ATCTCCACGTAGGCAAAGCC
F: GTCAGTGGACAGATGCTGTA
R: CGCCTTGATGAGCTCTCTAA

ESR1

Estrogen receptor 1

Hormonal activity

NM_001081772.1

F: ACGATGCCACCAGACCATTT
R: CATGTGAACCAGCTCCCTGT

(table cont’d.)
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Symbol

Gene Name

Protein Function

Accession Number

Sequence 5’–>3’

HK2

Hexokinase 2

Synthesis of
glycogen

NM_001081776.1

F: CTCAGAGCGGCTCAAGACAA
R: GCACACCTCCTTGACGATGA

SPLA2

Secretory
phospholipase A2

Synthesis of
prostaglandins

XM_005607005.1

F: AGGCAGTCGCTTGGAAGTAT
R: CGGAAATCCAGCAAATGCCC

CTGF

Connective tissue
growth factor

Endometrial cell
proliferation and
differentiation

XM_001503316.4

F: TGCAGCAGCGTGAAGACATA
R: GTAATGGCAGGCACAGGTCT

(table cont’d.)
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2.2.8. Statistical Methods
Statistical analysis was performed with GraphPad Prism Version 9.0.0 (GraphPad Software
Inc., San Diego, CA, USA). The normal distribution of data was analyzed by Shapiro-Wilk test.
Non-normal data were log-transformed before applying parametric testing. An equivalent
nonparametric test was used for the data that could not be normalized. Normally distributed data
were expressed as mean ± SEM and non-normal data were expressed as the median and
interquartile range (IQR). Data for embryo recovery rate was analyzed by Fisher’s exact test
followed by Bonferroni correction. Data for cervical tone, embryonic diameter, stage of embryo
development, quality grade, and percentage of non-viable cells were analyzed using KruskalWallis test followed by Dunn’s multiple comparison test. Data for fluorescence intensity of the
capsule was analyzed using one‐way ANOVA followed by Holm-Šídák test. Real-time RT-PCR
results were analyzed using one‐way ANOVA followed by Benjamini-Hochberg procedure for
multiple comparisons using the false discovery rate correction with a q value <0.05.
Concentrations of plasma progesterone in Experiment 1 were analyzed by Friedman test followed
by Dunn’s multiple comparison test. Concentrations of plasma progesterone in Experiment 2 were
analyzed by Mann-Whitney U test and Kruskal-Wallis test followed by Dunn’s multiple
comparison test accordingly. Concentrations of plasma altrenogest were analyzed by paired
Student’s t-test. Pregnancy outcomes for the Ctrl and AL-Suppl cycles in Experiment 2 were
compared using McNemar’s test. The diameters of embryonic vesicles in Experiment 2 were
analyzed by two‐way ANOVA followed by post-hoc analyses using Holm-Šídák test. Statistical
signiﬁcance for all data analyses was set at p <0.05.
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2.3. Results
Experiment 1
A total of six complete sets of day 7 equine embryos were collected in all three groups,
with two mares each producing two embryos in AL and AL-Suppl cycles (Mares 7 and 8),
respectively (Figure 2.1 and Table 2.2). For those two mares, one mare became anestrous before
collection of the third embryo in that year, while another mare developed fungal endometritis after
collection of two embryos. Two embryos were collected from two mares with double ovulations
(Mares 1 and 3), each from Ctrl and AL cycles, respectively. No difference in the rate of successful
embryo collection was found among the three groups (p ≥0.05; Table 2.3). The diameters of
embryos from AL cycles were significantly smaller than those in Ctrl and AL-Suppl cycles. The
median (IQR) embryo diameter was 270 μm (247-481 μm) for Ctrl embryos, 167 μm (165-181
μm) for AL embryos, and 399 μm (307-410 μm) for AL-Suppl embryos. No morulae were
collected in any group. Morphological embryo evaluation revealed that the developmental stage
in Ctrl and AL-Suppl cycles significantly differed from that of embryos in AL cycles. In Ctrl
cycles, 57.1% (4/7) of embryos collected on day 7 were classiﬁed as blastocysts and 42.9% (3/7)
were classiﬁed as expanded blastocysts (Table 2.3). In contrast, embryos collected from AL cycles
on day 7 were 100% (9/9) early blastocysts (Table 2.3). In AL-Suppl cycles, 12.5% (1/8) were
classiﬁed as an early blastocyst, 12.5% (1/8) were classiﬁed as a blastocyst, and 75.0% (6/8) of
embryos collected were classiﬁed as expanded blastocysts. No difference in the quality grade of
the embryos and the percentage of DAPI-positive cells (viability stain) was observed among all
groups (p ≥0.05). While the embryonic capsule was detected in all embryos collected across the
three experimental groups, no difference was found in the mean capsule-specific ﬂuorescence
intensity among the three groups (p ≥0.05). The cervical tone significantly differed among the
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Table 2.2. Diameter, developmental stage, and quality grade of embryos recovered on day 7 after ovulation from eight mares in
control, aluteal, and aluteal-supplemented cycles.
Mare ID
Control
Aluteal
Aluteal-supplemented
Diameter
(μm)

Embryo
Stage

Quality
Grade

Diameter
(μm)

Embryo
Stage

Quality
Grade

Diameter
(μm)

Embryo
Stage

Quality
Grade

Ex. B.
Ex. B.
Ex. B.
Ex. B.

1
1
1
2

165

Ea. B.

1

397

Ex. B.

1

2
3

481
853
365
247

1
2

Ex. B.
Ex. B.
Ex. B.
N/A*
N/A$

1
1
1
N/A*
N/A$

2
2
2
1
1
3
1
2

Ex. B.
Ex. B.

268
182
270
N/A*
N/A$

Ea. B.
Ea. B.
Ea. B.
Ea. B.
Ea. B.
Ea. B.
Ea. B.
Ea. B.

408
400

4
5
6
7
8

161
190
205
172
166
167
165
168

280
410
387
424
167

Blast
Ex. B.
Ex. B.
Ex. B.
Ex. B.

1
1
1
1
2

1

*

Mare #7 became anestrous before collection of the third embryo in that year.
Mare #8 developed fungal endometritis after two embryo collections.
Abbreviation: N/A: not available; Ea. B.: Early blastocyst; Blast: blastocyst; Ex. B.: Expanded blastocyst.
$
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Figure 2.1. Equine embryos collected on day 7 after ovulation from the same mare in control,
aluteal, and aluteal-supplemented cycles. (A) An expanded blastocyst of grade 1 quality measuring
481 μm in diameter before ﬁxation collected in a control cycle, with prominent inner cell mass
(arrowheads) and a thin zona pellucida. (B) An early blastocyst of grade 1 quality measuring
165 μm in diameter before ﬁxation collected in an aluteal cycle. (C) An expanded blastocyst of
grade 1 quality measuring 397 μm in diameter before ﬁxation collected in an aluteal-supplemented
cycle. The embryo has prominent inner cell mass (arrowheads) and a thin zona pellucida. 4’,6diamidino-2-phenylindole (DAPI)-stained embryos in control (D), aluteal (E), and alutealsupplemented cycles (F). Blastomeres with positive signal (arrows) indicated non-viable cells.
Immunoﬂuorescent staining with ﬂuorescein-conjugated OC-1 (red) illustrates a well-developed
and continuous embryonic capsule present in equine embryos collected in control (G), aluteal (H),
and aluteal-supplemented cycles (I), with DAPI as a nuclear stain (blue).
Scale bar = 100 μm.
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Table 2.3. Inﬂuence of progesterone-deprivation (aluteal cycle) and altrenogest-supplementation
(aluteal-supplemented cycle) on day 7 equine embryos.
Control
Aluteal
Aluteal(Ctrl)
(AL)
supplemented
(AL-Suppl)
Rate of Successful Embryo
Collection

60% (6/10)

66.7% (8/12)

66.7% (8/12)

Median Diameter of Embryos
(± IQR)

270 μm
(247-481 μm) a

167 μm
(165-181 μm) b

399 μm
(307-410 μm) a

Embryo Developmental Stage*
Early Blastocyst

0% (0/7)

100% (9/9)

12.5% (1/8)

Blastocyst

57.1% (4/7)

0% (0/9)

12.5% (1/8)

Expanded Blastocyst

42.9% (3/7)

0% (0/9)

75.0% (6/8)

1
(1-1)

2
(1-2)

1
(1-1.8)

Median Percentage of DAPIstained Blastomeres (IQR)

1.4%
(0.7-4.8%)

2.8%
(1.4-6.6%)

2.0%
(1.1-3.8%)

Mean OC-1 Speciﬁc
Fluorescence (± SEM)

68.6 ± 5.4

78.6 ± 5.7

63.4 ± 6.5

Median Embryo Quality
Grade# (IQR)

ab

Within a row, medians without a common superscript are different from each other (p <0.05).
*The developmental stage of embryos in Ctrl and AL-Suppl cycles differed from embryos in AL cycles (p <0.05).
#
Quality grade 1: no abnormalities, spherical in shape, blastomeres with uniform size, color and texture; grade 2: minor
imperfections demonstrated by some extruded blastomeres, and slight irregularities in shape, size, color or texture;
grade 3: moderate imperfections demonstrated by a large percentage of extruded blastomeres, partial collapse of
blastocele, or moderate shrinkage of trophoblast from zona pellucida; grade 4: embryos had complete degeneration
and embryonic death (McCue & Squires 2015).
Abbreviation: Ctr: Control; AL: Aluteal; AL-Suppl: Aluteal-supplemented; IQR: interquartile range; DAPI: 4’,6diamidino-2-phenylindole.
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three groups. All mares in AL cycles had poor cervical tone (12/12; 100%), whereas all mares in
Ctrl cycles had good cervical tone (10/10; 100%). The cervical tone in AL-Suppl cycles was
classified as poor to fair (poor: 16.7%, 2/12; fair: 10/12; 83.3%). The intra-assay and inter-assay
coefficients of variation for progesterone assay were 5% and 9%, respectively. In Ctrl cycles, a
rise in progesterone was observed after ovulation (Figure 2.2). In contrast, the median daily
concentrations of plasma progesterone in AL and AL-Suppl cycles remained below 1.0 ng/mL
from day 0 until embryo collection on day 7. The median daily concentrations of plasma
progesterone in Ctrl cycles were significantly higher than those in AL-Suppl cycles and AL cycles
beginning at day 2 and 3, respectively.
To evaluate the endometrial environment in Ctrl, AL, or AL-Suppl cycles, selected
endometrial transcripts for embryonic growth and development were determined using real-time
RT-PCR (Figure 2.3). We found that expressions of P19 and HK2 in AL cycles were significantly
lower compared with those in Ctrl and AL-Suppl cycles. In contrast, expressions of ESR1, SPLA2,
and SCGB1A1 in AL cycles were significantly higher than those in Ctrl and AL-Suppl cycles.
Expressions of these transcripts were also significantly higher in AL-Suppl cycles compared with
Ctrl cycles. The expression of ACP5 in Ctrl cycles was significantly lower compared with those
in AL and AL-Suppl cycles. No difference was found among groups in expressions of PGR and
CTGF (p ≥0.05).
Experiment 2
To evaluate the efficacy of long-acting injectable altrenogest in maintaining pregnancy,
mares were treated with altrenogest on day 0 (ovulation) and day 12, and pregnancy rates were
determined on days 12 and 24 (Table 2.4). Embryonic heartbeat was detected on days 21 and 24
in both groups (Figure 2.4). On day 12, six and four out of eight mares were pregnant in Ctrl and
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Figure 2.2. Median (interquartile range) daily concentrations of plasma progesterone in control
(Ctrl), aluteal (AL), and aluteal-supplemented (AL-Suppl) cycles. During the aluteal cycles and
aluteal-supplemented cycles, mares received serial administration of PGF2α immediately after
ovulation twice daily on days 0, 1, and 2, then once daily on days 3 and 4 resulting in the median
daily concentrations of plasma progesterone remaining below 1.0 ng/mL. Mares in alutealsupplemented cycles received an additional injection of long-acting altrenogest on day 0 (arrow).
Plasma progesterone profiles in AL and AL-Suppl cycles contrast with the control cycle where a
rise in progesterone after ovulation was observed. The median daily concentrations of plasma
progesterone differed between control (Ctrl) and aluteal-supplemented (AL-Suppl) cycle
beginning on day 2 until day 7, while concentrations of plasma progesterone differed in control
(Ctrl) vs. aluteal (AL) cycles beginning on day 3 until day 7. #Control group is significantly
different from AL-Suppl group. *Control group is significantly different from both AL and ALSuppl groups.
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Figure 2.3. Fold change of transcript expression in endometrium 7 days after ovulation. RNA was
extracted from the endometrium from mares in the control (Ctrl; n=6), aluteal (AL; n=3), and
aluteal-supplemented (AL-Suppl; n=8) cycles for real-time reverse transcription polymerase chain
reaction. Six of eight transcripts evaluated were differentially expressed in the endometrium in AL
or AL-Suppl cycles when compared with Ctrl cycles. Two transcripts, P19 and HK2, were
downregulated, and four transcripts, SCGB1A1, ACP5, ESR1, SPLA2, were upregulated in AL
cycles when compared with Ctrl cycles. Four transcripts, SCGB1A1, ACP5, ESR1, SPLA2, were
upregulated in AL-Suppl endometrium (* = p <0.05; ns = p ≥0.05).

Table 2.4. Pregnancy maintenance in control and aluteal-supplemented cycles.
Group
Control
Aluteal-supplemented
(Ctrl)
(AL-Suppl)

#

Pregnancy Rate on day 12

75% (6/8)

50% (4/8)

Pregnancy Rate on day 24

75% (6/8)

25% (2/8) #

Two mares lost the pregnancy on day 21 and day 24 respectively.
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Figure 2.4. Representative ultrasonographic images of the embryonic vesicles in the uterus from
mares during aluteal-supplemented cycles. Mares received eight serial injections of PGF2α starting
within 12 hours after ovulation and a long-acting injectable altrenogest on days 0 (ovulation) and
12. The size of the vesicle was measured by transrectal ultrasonography on days 12, 15, 18, 21 and
24 after ovulation. The cursor line demonstrates the maximum diameter of the embryonic vesicle.
On days 21 and 24, the embryonic heartbeat was detected in the embryo proper by Doppler
ultrasonography. The scale to the right of the image is in centimeters.

AL-Suppl cycles, respectively. On day 24, while all six mares remained pregnant in Ctrl cycles,
only two mares were found pregnant in AL-Suppl cycles. Collapsing embryonic vesicles without
a detectable embryo heartbeat were found in one mare on day 21 and another mare on day 24 in
the AL-Suppl cycle. However, no statistical significance was found in pregnancy rates between
groups on both days (p ≥0.05). The size of the embryonic vesicle did not differ between Ctrl and
AL-Suppl cycles from days 12 to 24 (p ≥0.05; Figure 2.5). While the size of the embryonic vesicle
was significantly larger when compared with the previous measurement until day 21 in Ctrl cycles,
embryonic growth was not significant afterward until day 24 (p ≥0.05). In AL-Suppl cycles, the
increase in the size of the embryonic vesicle was only significant on day 15 but not thereafter.
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Figure 2.5. Mean (± SEM) diameter of embryonic vesicle in control (Ctrl) and alutealsupplemented (AL-Suppl) cycles. Mares in AL-Suppl cycles received eight serial injections of
PGF2α starting within 12 hours after ovulation and a long-acting injectable altrenogest on days 0
(ovulation) and 12. The size of the embryonic vesicle was measured by transrectal ultrasonography
on days 12, 15, 18, 21 and 24 after ovulation. The size of the embryonic vesicle did not differ
between Ctrl and AL-Suppl cycles from day 12 to 24 (p ≥0.05).

To elucidate the role of progestational hormones in maintaining early pregnancy,
concentrations of plasma progesterone and altrenogest were measured. The rise of progesterone
was detected beginning on day 2 until the day of embryo recovery (day 24), and the concentrations
were significantly higher in Ctrl cycles compared with AL-Suppl cycles, regardless of pregnancy
status (Figure 2.6). When each group was divided into pregnant and non-pregnant mares, we found
that plasma progesterone level in control non-pregnant (Ctrl-NP) mares were not significantly
different from control pregnant (Ctrl-P), aluteal-supplemented pregnant (AL-Suppl-P), and
aluteal-supplemented non-pregnant (AL-Suppl-NP; p ≥0.05). In contrast, plasma progesterone of
mares in Ctrl-P cycle was significantly higher than that of mares in both AL-Suppl-P and ALSuppl-NP cycles. No second ovulation was detected in all mares until day 24 or pregnancy loss.
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Figure 2.6. Median (interquartile range) concentrations of plasma progesterone in control (Ctrl)
and aluteal-supplemented (AL-Suppl) cycles in pregnant (P) and non-pregnant (NP) mares.
Mares in AL-Suppl cycles received eight serial injections of PGF2α starting within 12 hours after
ovulation and a long-acting injectable altrenogest on days 0 (ovulation) and 12. (A) Plasma
progesterone level in Ctrl (n=8) and AL-Suppl (n=8) cycles, regardless of pregnancy status. The
rise of progesterone was detected beginning on day 2 until the day of embryo recovery (day 24)
in Ctrl cycles. *Ctrl cycle is significantly different from AL-Suppl cycle. (B) Plasma
progesterone level in pregnant and non-pregnant mares in both cycles. Plasma progesterone level
in control non-pregnant (Ctrl-NP; n=2) mares were not different from control pregnant (Ctrl-P;
n=6; p ≥0.05), aluteal-supplemented pregnant (AL-Suppl-P; n=4; p ≥0.05), and alutealsupplemented non-pregnant (AL-Suppl-NP; n=4; p ≥0.05). *Ctrl-P cycle is significantly different
from both AL-Suppl-P and AL-Suppl-NP cycles.
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Figure 2.7. Concentrations of plasma altrenogest in aluteal-supplemented (AL-Suppl) cycles in
mares. Mares in AL-Suppl cycles received eight serial injections of PGF2α starting within 12 hours
after ovulation and a long-acting injectable altrenogest on days 0 (ovulation) and 12. The mean
(±SEM) concentration of plasma altrenogest was higher two days after altrenogest injection (15.5
± 2.5 ng/mL) compared with 12 days after injection (1.9 ± 0.8 ng/mL; p <0.05). Only mare A was
found pregnant on day 12.

The concentration of plasma altrenogest was significantly higher on two days after altrenogest
injection compared with 12 days after injection (Figure 2.7).
2.4. Discussion
Using an induced aluteal pregnancy model in mares, we found that equine embryos with
adequate quality and capsule formation, despite developmentally delayed, can be collected on day
7 after ovulation. A significantly improved embryo quality was observed when compared with that
of aluteal day 8 embryos as described in a previous study (Leisinger et al. 2018). Contributing
factors to the greater quality of day 7 vs. day 8 aluteal embryos may be related to a shorter stay of
day 7 embryos in a progestagen-deprived uterus. Studies about the effects of progestagen on the
female reproductive tract mainly focus on the uterus, and only a few studies have been performed
to investigate the uterine tubes after ovulation or during early pregnancy. Similar to the findings
in the study of day 8 aluteal embryos, ovariectomy performed shortly after mating resulted in
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degenerate blastocysts collected between days 4 and 7 from the uterus of rabbit does (Corner
1928). Ovariectomy after ovulation provides an absolute means to study the significance of ovarian
steroid hormones in embryonic development by promptly removing the source of hormone
production; however, researchers suggested that the surgical stress and surgical trauma on the
uterine tube may have a major adverse effect on embryo viability (Vinijsanun & Martin 1991).
Also, this procedure is irreversible. The aluteal pregnancy model used in the present study provides
an alternative approach to collect multiple embryos under a progesterone-deprived environment
from the same individual repeatedly.
Whether the deprivation of progesterone affects the tubal-uterine transportation of embryos
remains undetermined. Contradictory results have been reported in different species (Roblero &
Garavagno 1979, Paksy et al. 1992, Akison & Robker 2012), which may suggest there is a
difference between species. Researchers reported that progesterone supplementation in a natural
pregnancy did not hasten the tubal-uterine transportation of embryo in mares (Hinrichs & Watson
1991). In a normal pregnancy, the equine embryo moves along the uterine tube after fertilization
and enters into the uterus between 130 to 144 hours (5.5-6 days) after ovulation (Freeman et al.
1991). In agreement with this, studies reported that the embryo recovery rate on days 7 to 9 after
ovulation was higher compared with that on day 6 due to a possible failure of some embryos to
enter the uterus by day 6 (Squires et al. 1985, Battut et al. 1997). In our study, the rate of successful
embryo collection on day 7 in AL cycles was comparable to Ctrl cycles and the quality grades of
AL embryos were not different from Ctrl ones. This is in contrast to the reduced embryo quality
grade of day 8 AL embryos found in one study (Leisinger et al. 2018). Based on the embryo
recovery rate of AL embryos in the present study, we suggest that delayed tubal-uterine
transportation likely did not contribute to the worsened embryo quality observed on day 8 AL
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embryos as reported previously. The median (IQR) embryo diameter of day 7 AL embryos in the
present study (167; 165-181 μm) and the mean (± SEM) embryo diameter on day 8 AL embryos
in the previous study (171 ± 5 μm) were consistent with the reported mean (±SEM) diameter of
embryos aged day 6 to 6.5 after ovulation (168 ± 5 μm and 186 ± 9 μm; (Freeman et al. 1991,
Battut et al. 1997). The similar embryonic sizes suggest day 7 and day 8 AL embryos did not attain
considerable development in size following their entry into the progesterone-deprived uterus and
even further became degenerated by day 8. Taken together, the findings of the unaffected embryo
recovery rate and the adequate quality of embryos collected on day 7 in aluteal cycles in this study
provides clues that progestagens may not be as critical for tubal embryonic development as it is
for uterine-stage embryos. We speculate that only a basal level of progesterone is required for the
survival of tubal-stage embryos and normal tubal-uterine transportation of embryos in mares. How
the additional day in the progesterone-deprived uterus would aggravate the deterioration of embryo
quality remains to be investigated. As the embryo quality on day 7 in the AL cycle was comparable
to those from Ctrl cycle, further studies transferring day 7 aluteal embryos to recipient mares are
warranted to determine the potential of these embryos to produce viable pregnancies.
An adequate uterine environment is critical for embryonic development. This is especially
important in equine pregnancy because of the prolonged period of preimplantation. Previous
studies demonstrated that the transcriptome of the endometrium and uterine secretions were
adversely affected by an experimentally induced hypoluteal diestrual environment (Beyer et al.
2019, Leisinger et al. 2019). Uterocalin (encoded by P19), uteroglobin (encoded by SCGB1A1),
and uteroferrin (encoded by ACP5) are major endometrial secretory products. Hexokinase 2
(encoded by HK2) is a key regulator of glycogen accumulation in the equine endometrium. The
transcript expressions of P19, SCGB1A1, ACP5, and HK2 have been reported to be progesterone-

59

mediated in mares (Ellenberger et al. 2008, Hayes et al. 2012, Bramer et al. 2017). Since
altrenogest is a potent agonist of progesterone receptor (McRobb et al. 2008), altrenogest treatment
restored the expression of P19 in our study. The downregulated expressions of P19 and HK2 were
reversed by the supplementation of altrenogest in AL-Suppl cycles. Uterocalin (P19) is the major
component of endometrial secretion, i.e., histotroph. Uterocalin is known to have an important role
as a secreted lipocalin that transports small lipophilic substances from the endometrium through
the embryonic capsule to the embryo. Our results suggest the AL-Suppl cycle provides a more
favorable environment for embryonic development compared with AL cycles. On the other hand,
both expressions of SCGB1A1 and ACP5 were upregulated in AL and AL-Suppl cycles in the
present study. This may be attributed to the treatment with PGF2α, which has been described in
one previous study (Hayes et al. 2012), regardless of the low progesterone in AL cycles. Moreover,
a study surprisingly showed that the circulatory level of 5α-dihydroprogesterone (DHP) increased
following treatment with altrenogest in late-term pregnant mares (Ousey et al. 2002). This
reproductive hormone is a 5α-reduced metabolite of progesterone but not altrenogest in horses
(Lampinen-Salomonsson et al. 2006, Conley et al. 2018). As a metabolite of progesterone, DHP
has been recently suggested to be the second endogenous potent progesterone receptor agonist in
early pregnancy in addition to progesterone (Scholtz et al. 2014, Conley et al. 2018). It has been
shown that DHP is capable of stimulating endometrial growth and progesterone-dependent gene
expression in mares, and more importantly, supporting pregnancy in PGF2α-treated mares at least
until day 27 after ovulation (Scholtz et al. 2014). Whether the progestational effect of altrenogest
on aluteal equine pregnancy observed in our study is mediated via DHP remains to be elucidated.
Furthermore, the expressions of SPLA2, ESR1, and PGR were reported to be inversely correlated
with progesterone concentration (Leisinger et al. 2019). As expected, the expression of SPLA2 and
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ESR1 increased in AL cycles (low progesterone) and were reduced in AL-Suppl cycles (altrenogest
supplementation) in our study. In contrast, no significant difference was found in the expression
of PGR among groups. We speculate one sample in Ctrl cycles was extremely high in expression
and possibly was an outlier. Surprisingly, the expression of PGR in AL-Suppl cycles was not
suppressed. We found that the level of altrenogest was significantly decreased on day 12 in
experiment 2. The altrenogest concentration may have already reached a low level on day 7, which
could explain the high expression of PGR in AL-Suppl cycles. Connective tissue growth factor,
encoded by CTGF, contributes to the maintenance of early pregnancy in mares by promoting
proliferation and differentiation of the endometrium and embryo via reciprocal interactions (Klein
2016b). A previous study suggested that the reduced expression of CTGF in the endometrial biopsy
collected on day 8 of the AL cycle may result from the interrupted embryo-uterine signaling
(Leisinger et al. 2019). Since most embryos collected on day 7 in all groups in our study were
considered of good quality grade, this result may suggest that the embryo-uterine signaling
remained intact.
This current study demonstrated that an embryonic capsule is present in the equine embryos
even in an extreme hypoluteal condition. The presence of the intact embryonic capsule is essential
for embryonic survival in vivo since no pregnancy could be produced from the embryo transfer of
capsuled-removed ex vivo embryos (Stout et al. 2005). Studies have shown that the capsule formed
in in vitro produced equine embryos are retarded and aberrant (Tremoleda et al. 2003). The
supplementation of uterocalin (P19), the major component of the capsule, into the culture medium
enhanced the formation of the capsule in vitro but the formation was not complete (Smits et al.
2012), suggesting the need for an additional maternal component. In support of this, regardless of
the expression of uterocalin in the maternal environment among different groups in this study,
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capsule formation was detected in all embryos, even in a hypoluteal environment. These results
support the hypothesis that capsule formation requires factors other than maternal uterocalin and
progesterone. It was suggested that day 8 aluteal embryos may show compensatory upregulation
of several transcripts related to capsule formation and nutrient uptake for a short period (Leisinger
et al. 2019), which may potentially contribute to the capsule formation observed in this study.
Therefore, maternal and embryonic factors facilitating capsule formation warrants further
investigation.
We found that long-acting injectable altrenogest can create an adequate endometrial
environment to support normal embryonic development until day 7 in an extreme hypoluteal
condition. However, compromised pregnancy was noted at a later stage on day 24 in the alutealsupplemented cycle. Uterine and cervical tone are useful indicators for evaluating equine
pregnancy since compromised pregnancy or pregnancy loss usually is preceded by a loss of uterine
tone (Holtan et al. 1979, Canisso et al. 2013). The evaluation of tone has also been used for
selecting recipient mares for embryo transfer (Carnevale et al. 2000), as well as assessing the
efficacy of progestational supplementation in mares (Canisso et al. 2013, Alonso et al. 2019,
Hornberger et al. 2019). Both endogenous and exogenous progestagens, in conjunction with
estrogen (either given exogenously or secreted by the embryo), cause increased tone of the uterus
and cervix in mares (Hayes & Ginther 1986). In this study, only cervical tone but not uterine tone
was measured for evaluating the effect of altrenogest supplementation on the reproductive tract in
Experiment 1 because multiple studies reported that uterine tone is not well distinguishable in early
diestrus between pregnant and non-pregnant mares (Van Niekerk 1965, Griffin et al. 1992,
Bonafos et al. 1994). In our study, the cervical tone was evaluated on day 7 (day of embryo
collection). All mares in Ctrl cycles had good cervical while it was poor in all AL cycles and
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mostly fair in AL-Suppl cycles. A previous study using altrenogest-treated ovariectomizedrecipient mares reported that mares receiving a lower dose of altrenogest also had poor cervical
tone, whereas mares given three times the standard dose of oral altrenogest (66 mg per mare) had
good cervical tone (Hinrichs et al. 1986). This may suggest an insufficient dosage of altrenogest
used in our study. Furthermore, compromised pregnancy was noted in mares in AL-Suppl cycles
at a later stage (day 21 and day 24). This is consistent with a previous study using the same
altrenogest formulation used in our study (Morrow & Burns 2007). In that study, luteolysis was
induced by PGF2α treatment in pregnant mares on day 12-16 after ovulation, and altrenogest was
given at the same time with a repeated injection 7 days later. Pregnancy was maintained for 7 days
after the first altrenogest injection, but all mares had pregnancy loss 12 days after the second
altrenogest injection. In contrast, a previous study from our laboratory showed that a single
injection of altrenogest given on day 5 after ovulation maintained pregnancy for at least 17 days
(Leisinger et al. 2016), albeit delayed embryonic development. In our study, the plasma altrenogest
level significantly decreased from day 2 to day 12 after injection. However, it is uncertain whether
the lower level of altrenogest on day 12 was below the required plasma concentration to maintain
pregnancy, which has not been reported in the literature. Together, our findings may suggest
insufficient dosage or efficacy of long-acting injectable altrenogest. The treatment regimen with
altrenogest to support early pregnancy requires further investigation.
Our results showed that altrenogest supplementation was able to counteract the effects of
PGF2α-induced luteal ablation on embryonic development. Accordingly, the median diameter,
development stage, and quality of embryos collected at day 7 in AL-Suppl mares were not different
from embryos collected from Ctrl mares, whereas AL embryos were small and developmentally
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retarded. These results suggest that serial PGF2α treatments do not directly affect early embryonic
development.
2.5. Conclusions
Equine embryos with adequate quality and capsule formation, despite being
developmentally delayed, can be collected on day 7 using the aluteal pregnancy model. Longacting injectable altrenogest can create a favorable endometrial environment to support normal
embryonic development until day 7 in an extreme hypoluteal condition. Future studies are required
to determine the treatment regimen with long-acting injectable altrenogest to maintain pregnancy
to a later stage in mares.
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CHAPTER 3. REPRODUCTIVE HORMONES OF PREGNANT MARES IN
EARLY ALUTEAL CYCLES AND REPRODUCTIVE PARAMETERS OF
THE SUBSEQUENT ESTRUS
3.1. Introduction
Prostaglandin F2α (PGF2α), is a commonly used luteolytic agent in equine breeding
management. The presence of a natural luteolysin produced from the endometrium was first
suggested in the 1970s by the observation of a prolonged luteal phase after hysterectomy (Ginther
1971). The role of PGF2α as the natural luteolytic agent was later elucidated by the findings of a
shortened diestrus with rapid return to estrus following the administration of exogenous PGF2α in
mares (Douglas & Ginther 1972). Thereafter, endogenous PGF2α metabolite in the uterine vein of
mares was identified (Douglas & Ginther 1976). The discovery of PGF2α has revolutionized
breeding management since it can effectively shorten the length of diestrus and reduce the
interovulatory intervals in mares.
There are rising concerns about the widespread use of exogenous PGF2α in mares in
diestrus because of potential complications related to reduced reproductive performance. A few
studies found that treatment with PGF2α in mares resulted in an increased incidence of the
hemorrhagic anovulatory follicle (HAF; Cuervo-Arango & Newcombe 2009a, Ginther & AlMamun 2009, Cuervo‐Arango & Newcombe 2010), which is a condition where follicles fail to
rupture, and the follicular cavity is filled with blood. However, one study found a low incidence
of HAF in mares treated with PGF2α (Burden et al. 2015). Inducing luteolysis with exogenous
PGF2α has been shown to induce a longer period of elevated concentrations of luteinizing hormone
(LH) than that following spontaneous luteolysis (Ginther et al. 2009a). An advanced stimulatory
LH environment has been proposed to contribute to the development of HAF (Ginther & AlMamun 2009). However, HAF could not be induced experimentally with the treatment with
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recombinant equine LH in other studies (Schauer et al. 2013, Bashir et al. 2016). Furthermore, a
series of experiments has been conducted in our laboratory using an in vivo mare model, namely
the aluteal model, in which mares were given serial injections of PGF2α upon detection of ovulation
to induce a persistently low progesterone environment characterized by failure of luteal formation
(Rubio et al. 2008, Coffman et al. 2014, Leisinger et al. 2018). No increase in the incidence of
HAF was observed in any of these studies.
Early exposure to high levels of LH after induction of luteolysis with PGF2α alters several
follicular fluid factors and may affect oocyte development and maturation (Schauer et al. 2013).
The effect of the administration of PGF2α during diestrus on the subsequent pregnancy rate is also
still controversial. Some studies reported lower pregnancy rates after the administration of PGF2α
(dinoprost; Lindeberg et al. 2002), whereas another study reported no effect on pregnancy rate
after the administration of a synthetic PGF2α analog (cloprostenol; Metcalf & Thompson 2010). In
one study evaluating the fertility of the induced estrus by serial administration of PGF2α (aluteal
protocol), the pregnancy rate on day 14 after the aluteal-induced estrus was not different from that
of the induced estrus after a single injection of PGF2α on day 10 after ovulation. For both early
diestrus treatment and mid-diestrus treatment groups, nine of ten mares were pregnant in that study
(Coffman et al. 2014). The pregnancy rate is reported to be decreased when the intervals from
PGF2α treatment to ovulation are less than six days compared with an interval of more than eight
days (Cuervo-Arango et al. 2015). On the other hand, treatment with PGF2α has been associated
with increased ovulation rates (Cuervo-Arango & Newcombe 2009a, Ginther & Al-Mamun 2009),
which may be due to a higher LH level before follicle deviation (Ginther et al. 2009a). Together,
since PGF2α could potentially alter the reproductive performance in mares, investigation on its
impact on mare’s reproductive parameters is critical.
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The aluteal cycle is defined as a persistent low plasma progesterone level (<1.0 ng/mL),
which can be induced with multiple injections of PGF2α in early diestrus, thus eliminating the luteal
phase (diestrus) between two ovulatory cycles. Induced aluteal cycles have been used to
investigate the effect of progesterone deprivation on embryonic development during early
pregnancy in mares (Leisinger et al. 2018). In Chapter 2 of this dissertation, we reported a delayed
embryonic development recorded for day 7 embryos of aluteal cycles. In contrast, embryos from
mares in aluteal cycles receiving supplementation with altrenogest (aluteal-supplemented cycle)
have comparable developmental stages to those collected from mares during normal, luteal cycles.
However, the dynamics of reproductive hormones in these different cycles have not yet been
investigated. Furthermore, the impact of multiple injections of PGF2α on the rate of successful
embryo collection in the subsequent cycle is unknown.
The objectives of this study were to investigate the profile of reproductive hormones in the
first seven days of aluteal cycles with or without altrenogest supplementation in pregnant mares
and to elucidate the reproductive parameters of estrous cycles induced after treatment. Due to the
negative feedback action of progesterone and altrenogest on LH release (Palmer 1985, Irvine &
Alexander 1997), we hypothesized that pregnant mares in early aluteal cycles would have a
sustained higher concentration of plasma LH level compared with control luteal cycles and alutealsupplemented cycles. We further hypothesized that mares in aluteal cycles would have an
increased number of follicles and consequently an increased incidence of multiple ovulations,
whereas the rate of successful embryo collections in estrous cycles induced after treatment would
not be impacted.
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3.2. Materials and Methods
3.2.1. Animals and Study Design
The study was approved by the Louisiana State University School of Veterinary Medicine
Institutional Animal Care and Use Committee. The work was performed at Louisiana State
University in Baton Rouge, LA from May to November 2018. The experimental animals were
handled in accordance with The Guide for the Care and Use of Laboratory Animals. Eight cyclic
light breed mares (Equus caballus) aged between five and ten years (mean ± SEM = 7.3 ± 0.6
years) were included in this study. Mares were kept in large pastures with covered sheds. They
were fed grain twice daily, and water and grass hay were available ad libitum.
Mares were examined three times a week by transrectal ultrasonography (SonoSite Edge,
FUJIFILM SonoSite Inc., Bothell, WA) to monitor their estrous cycles. Estrous mares having a
follicle ≥35 mm in diameter with uterine edema observed ultrasonographically, were treated with
2000 IU of human chorionic gonadotropin intravenously (hCG; Chorulon, Merck Animal Health,
Kenilworth, NJ) once for induction of ovulation. Mares were artiﬁcially inseminated with extended
fresh semen containing ≥1 x 109 progressively motile spermatozoa from one stallion of known
fertility every other day until ovulation was detected. Transrectal ultrasonographic examinations
were performed twice daily (AM and PM) after insemination until detection of ovulation (day 0).
Upon ovulation, mares were randomly assigned to one of three treatment groups: control luteal
cycle (Ctrl), aluteal cycle (AL), or aluteal-supplemented cycle (AL-Suppl). The mares in AL
cycles were treated according to a protocol previously described (Coffman et al. 2014). Brieﬂy,
they were treated immediately after the detection of ovulation with 10 mg of dinoprost
tromethamine intramuscularly (a tromethamine salt of the naturally occurring PGF2α, Lutalyse,
Zoetis, Parsippany, NJ) twice daily on days 0, 1, and 2, and once daily on days 3 and 4. Mares in
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Ctrl cycles were treated with the same volume (2 mL) of saline solution intramuscularly on the
same schedule. Mares in AL-Suppl cycles were treated with serial PGF2α injections as mares in
AL cycles, and further treated with a single intramuscular injection of 225 mg of long-acting
altrenogest solution (BioRelease Altrenogest LA150, BET Pharm, Lexington, KY) upon detection
of ovulation on day 0.
Mares remained in the group assigned until a successful embryo collection. After a positive
embryo collection, they were assigned to another treatment group. Embryo collections were
performed on day 7 after ovulation. Mares were treated with 10 mg of PGF2α intramuscularly after
embryo collection. Daily blood samples were collected starting from the day of ovulation (day 0)
until embryo collection (day 7) in all three cycles. Plasma samples were harvested and stored at
-20 °C until assayed for progesterone, LH, and follicle-stimulating hormone (FSH).
The number of ovulations in each cycle was recorded. The cycles of multiple ovulations
indicated more than one ovulation. Both synchronous and asynchronous ovulations (≤ two days
from primary ovulation) were considered as multiple ovulations. Incidences of HAF and diestrous
ovulation were also recorded. Diestrous ovulation was not considered multiple ovulations in this
study. HAF was not included in either single or multiple ovulations. When HAF occurred without
accompanying normal ovulation, embryo collection was not performed. The affected mares were
treated with the aluteal treatment protocol as described previously (Davolli et al. 2018). They were
allowed to ovulate naturally for a cycle after treatment and then return to their original assigned
group. When HAF occurred with accompanying normal ovulation(s), the mare remained in the
treatment group and embryo collection was performed.

69

3.2.2. Hormone Assays
Frozen plasma samples were thawed and analyzed for progesterone, LH, and FSH.
Concentrations of plasma progesterone were determined by a progesterone radioimmunoassay
(RIA), using commercially available kit reagents (ImmuChem Double Antibody, 125I RIA Kit, MP
Biomedicals, Costa Mesa, CA), and the assay sensitivity was 0.05 ng/mL. Concentrations of LH
and FSH were determined by radioimmunoassays previously validated for equine plasma
(Thompson Jr et al. 1983a, Thompson Jr et al. 1983b). The sensitivity of the assays was 0.2 ng/mL
for LH and 1.4 ng/mL for FSH.
3.2.4. Statistical Methods
Statistical analysis was performed with GraphPad Prism Version 9.0.0 (GraphPad Software
Inc., San Diego, CA, USA). The normal distribution of data was analyzed by Shapiro-Wilk test.
Non-normal data were log-transformed before applying parametric testing. An equivalent
nonparametric test was used for the data that could not be normalized. Normally distributed data
were expressed as mean ± SEM, and non-normal data were expressed as the median and
interquartile range (IQR). Concentrations of plasma progesterone were analyzed by Friedman test
followed by Dunn’s multiple comparison test. Concentrations of plasma LH and FSH were
analyzed by one-way ANOVA with repeated measures followed by Holm-Šídák test. The rate of
multiple ovulations and the rate of HAF in the subsequent estrus were analyzed by Fisher’s exact
test followed by Bonferroni correction. The average ovulation rate in the subsequent estrus and the
interovulatory interval were analyzed by one-way ANOVA followed by Holm-Šídák test.
Statistical signiﬁcance for all data analyses was set at p <0.05.
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3.3. Results
The intra-assay and inter-assay coefficients of variation were 5% and 9% for progesterone,
6% and 9% for LH; and 7% and 11% for FSH, respectively. The median daily concentrations of
plasma progesterone in Ctrl cycles were significantly higher than those in AL-Suppl cycles and
AL cycles beginning at days 2 and 3, respectively (Figure 3.1). Mean concentrations of plasma LH
were significantly greater in AL cycles than the other two cycles from days 1 to 7, along with mean
concentrations of plasma LH being greater in Ctrl cycles than those in AL-Suppl cycles on days 1
and 2 (Figure 3.1). No difference in plasma concentrations of FSH was found among the three
groups (p ≥0.05). For mares in Ctrl cycles, the concentrations of progesterone started to increase
from day 2, whereas a decrease in LH concentration was observed from day 3 until day 7. In
contrast, after altrenogest injection, the mean concentration of LH was significantly lower on days
1 and 2. No diestrous ovulations were observed during the study period. In all cycles (n = 56)
across all three experimental groups, a total of eight cycles (14%) had one follicle undergoing
hemorrhagic anovulation (Table 3.1). These eight cycles of HAF were observed in three mares,
which included two, three, and three incidences of HAF from each mare, respectively. A HAF
with accompanying normal ovulation occurred zero, three, and one times in Ctrl, AL, and ALSuppl cycles, respectively (Figure 3.2). After excluding the cycles that only have a HAF without
accompanying normal ovulation, the occurrence of multiple ovulations was significantly greater
in AL cycles (62.5%; 10/16) compared with that of AL-Suppl cycles (13.3%, 2/15), but not Ctrl
cycles (28.6%, 6/21; p =0.0516). The mean number of ovulations in the subsequent estrus was
significantly higher after the AL treatment when compared with the other two treatments. No
differences were found in the incidence of HAF or the rate of successful embryo collection among
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Figure 3.1. Daily concentrations of plasma progesterone, luteinizing hormone (LH), and folliclestimulating hormone (FSH) in control (Ctrl), aluteal (AL), and aluteal-supplemented (AL-Suppl)
cycles. Mares in aluteal cycles received twice-daily administration of PGF2α on days 0, 1, and 2,
then once daily on days 3 and 4. Arrow indicates an additional injection of long-acting altrenogest
in AL-Suppl cycles. (A) Median (± interquartile range) concentrations of plasma progesterone.
*Ctrl cycle is significantly different from AL and AL-Suppl cycles. #Ctrl cycle is significantly
different from AL-Suppl cycle. (B) Mean (±SEM) concentrations of plasma LH. *AL cycle is
significantly different from AL-Suppl and Ctrl cycles. #Ctrl cycle is significantly different from
AL-Suppl cycle. (C) Mean (±SEM) concentrations of plasma FSH.
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Table 3.1. Reproductive parameters of the subsequent estrus after control, aluteal, and alutealsupplemented treatments.
Control
Aluteal
Aluteal(Ctrl)
(AL)
supplemented
(AL-Suppl)
28.6% (6/21) a, b

62.5% (10/16) b

13.3% (2/15) a

Mean Number of Ovulations
(± SEM)

1.38 ± 0.09 a

1.81 ± 0.19 b

1.13 ± 0.09 a

Hemorrhagic Anovulatory
Follicles

12.5% (3/24)

18.8% (3/16)

12.5% (2/16)

Successful Embryo Collection

69.2% (9/13)

62.5% (5/8)

61.5% (8/13)

Mean Interovulatory Interval
(Days ± SEM)

17.0 ± 0.4 a

12.7 ± 0.7 b

15.9 ± 0.6 a

Multiple Ovulations

Within a row, medians or means without a common superscript are different from each other (p <0.05).

experimental groups (p ≥0.05). The mean interovulatory interval (days ± SEM) of AL cycles (12.7
± 0.7) were significantly shorter than that of Ctrl (17.0 ± 0.4) and AL-Suppl cycles (15.9 ± 0.6).
3.4. Discussion
In this study, we found that the mean concentrations of plasma LH were greater in AL
cycles compared with those in Ctrl and AL-Suppl cycles. In addition, mares in AL cycles had an
increased number of follicles and an increased rate of multiple ovulations, without an increased
rate of HAF or an impact on the rate of successful embryo collection. Mares have a unique
prolonged LH periovulatory surge, and the levels of LH reach the maximum at one to two days
after ovulation. Subsequently, its release is inhibited by gradually increasing progesterone (Evans
& Irvine 1975). In contrast, mares in AL cycles had an extremely low progesterone level for the
first seven days after ovulation in our study. This likely explains the sustained LH level due to the
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Figure 3.2. Representative ultrasonographic images of the left and right ovaries from a mare in a
control cycle on days 1 and 3 (day 0 = ovulation). (A) Day 1: The left ovary contained one
hyperechoic structure (arrows), which represents the corpus hemorrhagicum. (B) Day 1: The right
ovary contained an unruptured follicle with ﬂoating hyperechoic specks that began to form strands,
representing a hemorrhagic anovulatory follicle. (C) Day 3: The corpus hemorrhagicum shown in
(A) in the left ovary has transitioned to an early corpus luteum (arrows). (D) Day 3: The same
hemorrhagic anovulatory follicle shown in (B) contained networks of hyperechoic fibrin strands.
The scale to the right of the image is in centimeters.
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loss of progesterone-mediated negative feedback. Previous studies have reported that both
exogenous progesterone and altrenogest exert an inhibitory effect on LH release (Evans et al. 1982,
Palmer 1985). Since the injectable altrenogest was given on the day of ovulation (day 0) in our
study, the early inhibitory effect by altrenogest resulted in low LH levels on days 1 and 2 in ALSuppl cycles compared with those in Ctrl cycles. The lack of significant differences in the FSH
level among groups in this study was also supported by previous reports showing that luteal
progesterone or altrenogest supplementation do not directly affect FSH levels (Evans & Irvine
1975, Palmer 1985). Intriguingly, mares had an increased rate of multiple ovulations in the alutealinduced estrus in our study. This may be attributed to the persistently elevated LH level noted in
AL cycles after ovulation as suggested by one previous study that found the development of
multiple ovulatory follicles to be preceded by greater concentrations of plasma LH than that
preceding cycles with one ovulatory follicle (Ginther et al. 2009a). Similarly, another study
reported that number of mares with double ovulations tended the number of mares with double
ovulations tended to be greater when mares were treated with 10 mg of PGF2α intramuscularly on
day 3 after ovulation when compared with those that received the treatment on day 10; however,
75% of those mares (12 of 16) only underwent partial luteolysis after treatment (Bergfelt et al.
2006).
The formation of HAF has been reported as a potential complication in mares treated with
PGF2α in diestrus (Cuervo‐Arango & Newcombe 2010), albeit controversial among different
studies. The underlying pathophysiology is thought to involve PGF2α-induced luteolysis with a
subsequent high LH level that leads to an increased rate of HAF (Ginther et al. 2009a). However,
treatment with recombinant equine LH failed to induce the occurrence of HAF in experimental
mares (Bashir et al. 2016). Our study revealed similar results, where earlier exposure to a high
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concentration of LH starting from day 0 in aluteal cycles did not lead to an increased rate of HAF
in pregnant mares, suggesting that early exposure to LH does not predispose mares to the
development of HAF. In our study, HAF occurred in all three experimental groups. Therefore, the
repeated injections of PGF2α in early diestrous mares did not increase the incidence of HAF, as
observed in previous studies performed by our laboratory (Rubio et al. 2008, Coffman et al. 2014,
Leisinger 2018). In the present study, HAFs were found in three out of eight mares in the present
study, and all these events only occurred late in the breeding season. Our findings are consistent
with previous studies that reported a greater occurrence of HAF in the late ovulatory season
(September - November) than early (April - August; Gastal et al. 1998, Lefranc & Allen 2003).
However, conflicting findings have been shown in clinical retrospective studies where no
seasonality was observed in the occurrence of HAF (Cuervo-Arango & Newcombe 2009b), or the
majority of HAF occurred from May to August (Cuervo‐Arango & Newcombe 2010). While
differences in animal age, geographic location, breed, and treatment regimen may all contribute to
the different results among studies, most mares become pregnant in the early breeding season in a
clinical setting or would not present for breeding management late in the breeding season.
Therefore, the true incidence of HAF in the late breeding season may be obscured by these
contributing factors. Future studies should consider a study design where mares are observed for
all months to allow investigation of the prevalence of HAF at different times of the year. Repeated
occurrence of HAF was observed in three mares in our study, which is consistent with the literature
where an increased incidence of HAF was described in some individual mares referred to as
“repeater” mares (Ginther et al. 2006).
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3.5. Conclusions
This study showed that mares in aluteal cycles developed a characteristic hormonal profile
of low plasma progesterone and persistently elevated plasma LH. The occurrence of multiple
ovulations in the subsequent estrus after undergoing an aluteal treatment was greater than those
after aluteal-supplemented or control treatments. The interovulatory intervals in AL cycles were
significantly shortened. The results of this study may lead to novel strategies to manipulate the
reproductive cycle of mares.
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CHAPTER 4. EFFECT OF CONSTANT-RATE INFUSION OF
PROSTAGLANDIN F2ALPHA DURING THE FIRST 24 HOURS AFTER
OVULATION ON LUTEAL FUNCTION
4.1. Introduction
Induction of luteolysis is commonly performed in equine breeding management. This is
achieved by the administration of exogenous prostaglandin F2α (PGF2α) or its analog during
diestrus to hasten the return to estrus and shorten the interovulatory intervals in mares (Coffman
& Pinto 2016). Increasing evidence indicates that complete luteolysis can be induced in mares
before day 5 after ovulation (Bergfelt et al. 2006, Holland & Pinto 2008, Rubio et al. 2008, Tosi
et al. 2008, Cuervo‐Arango & Newcombe 2012, Garcia‐Muñoz et al. 2017), which is prevailingly
assumed to be the minimum age of the corpus luteum (CL) required for induction of luteolysis.
Furthermore, serial injections of PGF2α starting immediately after ovulation can prevent early
luteal development (antiluteogenesis) and induce a progesterone-deprived environment in mares
(namely the aluteal cycle, plasma concentration <1.0 ng/mL). The PGF2α-induced aluteal cycle has
been used to study the development of early preimplantation embryos and uterine receptivity
during early pregnancy in mares (Leisinger et al. 2018, Leisinger et al. 2019). However, the current
validated antiluteogenic protocol employs eight injections of PGF2α given over the course of five
days after ovulation (Coffman et al. 2014).
Optimal dose and frequency are important to effectively induce luteolysis, especially
during early diestrus. As early as the detection of ovulation, the administration of PGF2α can impair
the development of the CL and reduce the concentration of blood progesterone in the following
days of the estrous cycle (Gunthle et al. 2000, Nie et al. 2003a). However, a resurgence of luteal
function may occur after PGF2α treatment when the dosage is insufficient (Troedsson et al. 2001,
Brendemuehl 2002). A stronger and longer suppression of luteal function and development could
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be achieved by increasing the dosage (Rubio et al. 2008, Pinto et al. 2014), and by extending the
treatment for a longer duration (Coffman et al. 2014). In mares, PGF2α secreted from the
endometrium reaches the ovary systemically to induce spontaneous luteolysis, in contrast to the
local counter-current exchange mechanism involving the uterine vein and the ovarian artery
documented in ruminants (Ginther 1998). The required PGF2α dose for inducing luteolysis is not
different between the systemic route and the local (intrauterine) route in mares (Douglas & Ginther
1975, Ginther et al. 2009b). Therefore, the constant-rate infusion (CRI) of PGF2α via intravenous
catheterization has been reported to create a simulation of the concentration of PGF2α in a natural
pulse to induce luteolysis in mares (Ginther et al. 2009c).
The equine CL has a five-fold greater sensitivity to PGF2α compared with the bovine due
to a higher luteal affinity and slower clearance (Kimball & Lauderdale 1975, Kimball &
Wyngarden 1977, Shrestha et al. 2012). As a result, the luteolytic dose of PGF2α may induce some
side effects, including profound sweating, colicky behavior, or excitement, which typically subside
within 20 to 30 minutes after PGF2α treatment (Coffman & Pinto 2016). To induce luteolysis
without eliciting appreciable side effects, the administration of two low doses of PGF2α 24 hours
apart has been proposed (Irvine et al. 2002).
To reduce the duration of treatments required for induction of an aluteal cycle, our main
objective in this study was to examine an alternative protocol using CRI of PGF2α. We aimed to
investigate the effect of continuous administration of exogenous PGF2α for the first 24 hours after
ovulation on the function of early developing CL and the following estrous cycle. Since the
metabolite of PGF2α, 13,14-dihydro-15-keto prostaglandin F2α (PGFM), has a longer half-life in
the peripheral circulation than PGF2α (Ginther et al. 2007b), it was used in the present study as an
analytical marker of PGF2α. We hypothesized that mares treated with CRI of PGF2α for 24 hours
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would maintain a persistently elevated plasma concentration of PGFM during the treatment period,
and the treated mares would develop aluteal cycles, i.e., plasma concentration <1.0 ng/mL, with
shortened interovulatory intervals after the treatment.
4.2. Materials and Methods
4.2.1. Study Design
The study was approved by the Louisiana State University School of Veterinary Medicine
Institutional Animal Care and Use Committee (IACUC). This experiment was performed from
August to October in two breeding seasons in 2019 and 2020. Four cyclic light breed mares (Equus
caballus) aged between six and nine years (mean ± SEM = 7.0 ± 0.7 years) and weighed 441 to
527 kg were used for this crossover-designed study. The experimental animals were handled in
accordance with The Guide for the Care and Use of Laboratory Animals. Mares were kept in large
pastures with covered sheds. They were fed grain twice daily, and water and grass hay were
available ad libitum.
Mares were examined three times a week by transrectal ultrasonography (ExaPad and
ExaGo; IMV imaging, France) to monitor their estrous cycles. Estrous mares having a follicle
≥35 mm in diameter with uterine edema observed ultrasonographically, were treated once with
2000 IU of human chorionic gonadotropin (hCG; Chorulon, Merck Animal Health, Kenilworth,
NJ) intravenously for induction of ovulation at 11:00 PM. On the day after induction, mares were
moved into stalls and indwelling intravenous catheters (14 gauge; MILACATH, MILA
International, Inc, Florence, KY) were placed and secured into jugular veins on both sides. The
catheters were removed at the time when they were returned to the pasture. Mares were examined
every two hours starting from 30 hours after induction (starting at 05:00 AM) to detect the
occurrence of ovulation. Upon detection of ovulation, mares were randomly assigned into control
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luteal (Ctrl) and treatment cycles (CRI) in year 2018 as the first and second cycles in this study.
For mares in CRI cycles, dinoprost tromethamine (a tromethamine salt of the naturally occurring
PGF2α, Lutalyse, Zoetis, Parsippany, NJ) diluted in lactated Ringer’s solution (MWI Veterinary
Supply, Boise, ID) was infused at a constant rate of 30 mL/h to provide approximately 1.5 µg/kg/h
of dinoprost tromethamine intravenously for 24 hours (approximately 16-19 mg of dinoprost
tromethamine in total per mare). In Ctrl cycles, only lactated Ringer’s solution was infused at the
same rate. In the 2019 breeding season, the same group of mares was assigned into a third aluteal
cycle (AL). They were handled and monitored as described in year 2018 except the treatment with
CRI was replaced by multiple bolus injections. They were treated with the 5-day antiluteogenic
protocol upon detection of ovulation as previously described (Coffman et al. 2014). Brieﬂy, mares
were treated immediately after the detection of ovulation (day 0) with 10 mg of dinoprost
tromethamine intramuscularly twice daily on days 0, 1, and 2, and once daily on days 3 and 4.
Mares were examined for body temperature, respiratory rate, heart rate, gut sounds, and overall
demeanor/behavior every hour during the treatment. Adverse effects, if any, caused by PGF2α (e.g.,
sweating, restlessness, colic-like signs, tachycardia, and diarrhea) were recorded when mares were
in stalls. Mares returned to their original pasture after the first 25 hours of the sampling period.
Blood samples were collected in heparinized blood tubes hourly for the first 25 hours after
ovulation and then daily until the next ovulation. The blood tubes were immediately placed in an
ice-cold container upon collection and centrifuged at 4 °C for ten minutes. Plasma samples were
harvested and stored at -20 °C until assayed for progesterone and PGFM. After the assigned
treatment, mares were monitored reproductively until the next ovulation to record the
interovulatory interval.
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4.2.2. Hormone Assays
Frozen plasma samples were thawed and analyzed for progesterone and PGFM.
Concentrations of plasma progesterone were determined by radioimmunoassay (ImmuChem
Double Antibody, 125I RIA Kit, MP Biomedicals, Costa Mesa, CA), and the assay sensitivity was
0.05 ng/mL. Concentrations of plasma PGFM were measured using enzyme immunoassay
according to the manufacturer’s instructions (#516671, Cayman Chemical, Ann Arbor, MI)
previously validated for equine plasma (Keith et al. 2013), and the assay sensitivity was
16.3 pg/mL.
4.3. Results
One of the four mares in this study (Mare D) was euthanized for a non-reproductive
problem before enrolling in the third aluteal cycle. Therefore, data was only obtained from CRI
and Ctrl cycles for that mare. The interovulatory intervals of the first two mares treated with CRI
of dinoprost tromethamine at the rate of 1.5 µg/kg/h were not different from those in Ctrl cycles
(Table 4.1). Therefore, the rate of CRI for the remaining two mares was increased from 1.5 µg/kg/h
to 3.0 µg/kg/h with the IACUC’s approval. Due to the reduction in sample size per group in CRI
cycles (n=2), no statistical analysis was performed in this study. The hormonal data and
interovulatory interval were compared within individuals among different cycles (Figures 4.2 and
4.3). The interovulatory intervals in both CRI and Ctrl cycles were longer than that in aluteal cycles
(Table 4.1). Three mares had prolonged interovulatory intervals (> 25 days).
During the study period, there were no significant findings in vital signs in all mares,
including body temperature, respiratory rate, heart rate, and gut sounds. Profound sweating was
observed in all three mares in AL cycles within five minutes of each bolus intramuscular
administration of PGF2α, which lasted for about 20 minutes. One mare (Mare B) became recumbent
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Table 4.1. Interovulatory interval (days) in mares in control, aluteal, and constant-rate infusion
cycles.
Mare ID
Control
Aluteal
Constant-rate
Constant-rate
(Ctrl)
(AL)
Infusion
Infusion
(CRI-PGF2α)
(CRI-PGF2α)
1.5 µg/kg/h
3 µg/kg/h
Mare A
22
7
N/A
>25
Mare B

20

13

N/A

>25

Mare C

>25

13

20

N/A

Mare D

21

N/A

20

N/A

Abbreviation: N/A: not applicable.

and started rolling seven hours after the start of the CRI of PGF2α (3μg/kg/h); the colic-like signs
subsided within seven hours. Another mare (Mare A) became recumbent and started rolling six
hours after the start of CRI with PGF2α (3μg/kg/h), with colic-like signs lasting for one hour.
The intra-assay and inter-assay coefficients of variation for the progesterone assay were
5% and 9%, respectively. There was no difference in the concentrations of plasma progesterone
among the three cycles (Figure 4.1). In AL cycles, plasma progesterone concentrations were at the
baseline (<1.0 ng/mL) from one hour after treatment to the next ovulation. Contrary to our
hypothesis, plasma concentrations of progesterone started to increase from day 2 after ovulation
in both Ctrl and CRI cycles.
The intra-assay and inter-assay coefficients of variation for the PGFM assay were 9% and
12%, respectively. After a bolus treatment with PGF2α, mares in AL cycles had a surge in the
plasma concentrations of PGFM starting from one hour after treatment, which was followed by a
rapid decrease within four hours after treatment (Figure 4.2). In contrast, plasma concentrations of
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Figure 4.1. Plasma concentrations of progesterone in mares in aluteal (AL), constant-rate
infusion (CRI) of PGF2α, and control (Ctrl) cycles. Mares in CRI cycles were treated with CRI of
PGF2α at 1.5 µg/kg/h (n=2) or 3 µg/kg/h (n=2) for 24 hours. Mares in aluteal cycles (n=3)
received 10 mg of PGF2α intramuscularly twice daily for the first three days after ovulation and
once daily for the following two days. Mares in Ctrl cycles (n=4) were treated with CRI of
lactated Ringer’s solution at the same rate as the corresponding CRI cycle.
(fig. cont’d.)
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(fig. cont’d.)
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Figure 4.2. Plasma concentrations of 13,14-dihydro-15-keto prostaglandin F2α (PGFM) in aluteal
(AL), constant-rate infusion (CRI) of PGF2α, and control (Ctrl) cycles. Mares in CRI cycles were
treated with CRI of PGF2α at 1.5 µg/kg/h (n=2) or 3 µg/kg/h (n=2) for 24 hours. Mares in aluteal
cycles (n=3) received 10 mg of PGF2α intramuscularly twice daily for the first 3 days after
ovulation and once daily for the following 2 days. Mares in Ctrl cycles (n=4) were treated with
CRI of lactated Ringer’s solution at the same rate as the corresponding CRI cycle.
(fig. cont’d.)
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PGFM began to increase from one hour after the beginning of CRI and were sustained until the
end of CRI at hour 24. The area under the curve (AUC) for PGFM during the 25 hours of Ctrl,
CRI, and AL cycles were calculated (Figure 4.3). In all mares, the AUC for PGFM was higher in
the CRI cycle when compared with the Ctrl cycle, and it was also higher than that in the AL cycle
for Mare A (3 µg/kg/h group) and Mare C (1.5 µg/kg/h group).

Figure 4.3. The area under the curve (AUC) for 13,14-dihydro-15-keto prostaglandin F2α
(PGFM) during the 25 hours for each mare in aluteal (AL), constant-rate infusion (CRI) of
PGF2α, and control (Ctrl) cycles.

4.4. Discussion
In this study, the use of CRI of PGF2α at two different rates, 1.5 and 3 μg/kg/h, for 24 hours
starting within 2 hours after ovulation failed to induce a progesterone-deprived environment,
i.e., aluteal cycle, and did not result in a shortened interovulatory interval. The profile of plasma
progesterone concentrations and interovulatory intervals in mares receiving the CRI of PGF2α
resembled those of Ctrl cycles. In both CRI and Ctrl cycles, the rise in progesterone began on
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day 2 after ovulation, which was consistent with our findings in control luteal mares that did not
receive the CRI of PGF2α as described in Chapter 3. Three mares (mares A, B, and C) had
prolonged interovulatory intervals (> 25 days). Mares A and C had a prolonged luteal phase as
noted with a persistently elevated progesterone concentration, whereas mare B remained
anovulatory until 25 days after ovulation. These events may be attributed to the erratic cycles
usually happening in fall transition as this study was conducted in the late breeding season (August
- October; King et al. 2010). However, we cannot exclude the CRI treatment with PGF2α at a higher
rate as a contributing factor to the prolonged interovulatory interval as they were observed in both
mares A and B after they were treated with CRI of PGF2α at the rate of 3 μg/kg/h.
The AUC for PGFM during the 25 hours after ovulation was higher in the CRI cycles
compared with AL and Ctrl cycles for mares A and C, which supports the idea that CRI of PGF2α
can maintain relatively high plasma concentrations of PGFM during treatment. The concentrations
of plasma PGFM in the 5-day antiluteogenic protocol reached the peak at hour 1 and 13 (hours 0
and 12 were the time of intramuscular bolus injections) and gradually returned to baseline level at
hours 4 and 16, which was consistent with a previous study (Ferreira et al. 2018). The lower AUC
for PGFM in Mare B may be due to the extended period of rolling for 7 hours which potentially
impeded the flow of the fluid line for CRI.
The reasons for the failure of this protocol remain to be determined but may be
multifactorial, including desensitization or downregulation of receptors of PGF2α (FP receptors)
and insufficient dosage. Desensitization refers to the phenomenon of diminished cellular response
after prolonged or repeated treatment with an agonist. The mechanisms of desensitization may
involve a loss in cell surface receptors and uncoupling of the receptor from its effector protein
(Lefkowitz et al. 1983). In a previous study on sheep with an auto-transplanted ovary, in vivo
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desensitization of FP receptors was found after a one-hour infusion of a sub-luteolytic dose of
PGF2α. Researchers suggested that the desensitization of FP receptors might last up to nine hours,
which is comparable to the peak-to-peak interval of the natural PGF2α pulses during spontaneous
luteolysis in many domestic species (Lamsa et al. 1992). Desensitization of FP receptors was also
reported in other animal organs (Tachado et al. 1993, Gotoh et al. 1994). In our study, the constant
administration of PGF2α for 24 hours may have induced a similar effect. In order to avoid the
desensitization effect, serial bolus injections may be considered in a future study to evaluate the
effect of PGF2α on the first day after ovulation. An inhibitory pathway that regulates the transcript
expression of the FP receptor in the CL has been proposed (Anderson et al. 2001), in which a
decreased transcript expression of the FP receptor was observed after treatment with PGF2α in
ovine and bovine CL (Juengel et al. 1996, Tsai et al. 1998, Tsai & Wiltbank 1998). However, these
findings contradict the findings in equine and porcine studies (Estill et al. 1995, Beg et al. 2005).
More studies investigating the effect of PGF2α on the protein level of the FP receptor are warranted.
Another possible explanation for our findings is the insufficient dosage to achieve the target
plasma concentration required for inducing an aluteal cycle. In one study, 2.5 mg of PGF2α given
twice daily on days 0 to 2 after ovulation failed to induce complete luteolysis in all treated mares
(Rubio et al. 2008). However, some mares achieved complete luteolysis with an increased dose of
10 mg of PGF2α with the same treatment schedule in the same study. Similarly, another study
reported that an increased dose of cloprostenol administered at 80 to 112 hours after ovulation
promoted successful complete luteolysis in mares (Cuervo‐Arango & Newcombe 2012).
Therefore, an optimal concentration of treatment may be required to inducing aluteal cycle in early
diestrus. In addition, the CRI of PGF2α for two hours failed to induce complete luteolysis and
shortened interovulatory intervals in mares on day 8 after ovulation (Ginther et al. 2009b). These
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results may suggest the necessity for pulsatile delivery of PGF2α to effectively impair luteal
secretion in mares. Alternative protocols such as administering serial bolus injections warrant
further investigation.
An adverse event of colicky behavior was observed six and seven hours after the initiation
of CRI in two mares in this study. Exogenous PGF2α may induce transient side effects, which are
dose- and route-dependent. While adverse events were not reported with CRI of PGF2α for two
hours (1 mg in total, about 2 µg/kg/h) in one previous study (Ginther et al. 2009c), side effects
observed in our study may be attributed to the higher rate used because these mares received CRI
of PGF2α at 3 μg/kg/h. In support of this, side effects were not observed in mares receiving CRI of
PGF2α at a lower rate of 1.5 μg/kg/h in this study. Furthermore, intravenous administration of
PGF2α has been reported to induce more profound side effects in mares when compared with
subcutaneous or intramuscular routes (Cuervo‐Arango 2012). Therefore, side effects should be
closely monitored when a higher dosage of PGF2α is administered, especially when given
intravenously.
4.5. Conclusions
Our findings showed that plasma concentrations of PGFM were maintained by CRI of
PGF2α during the 24-hour treatment period. However, the proposed alternative protocol to induce
an aluteal cycle using CRI of PGF2α was not comparable to the standard antiluteogenic protocol
with eight injections of PGF2α given over the course of five days after ovulation. The CRI treatment
failed to induce a progesterone-deprived environment after ovulation, i.e., aluteal cycle and a
shortened interovulatory interval.
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CHAPTER 5. CONCLUSIONS
This dissertation research investigated the effect of endogenous and exogenous
progestagens on early embryonic development and reproductive parameters in the subsequent
estrus using an induced hypoluteal condition in pregnant mares (aluteal pregnancy model).
Using the aluteal pregnancy model, we found that developmentally delayed embryos with
adequate quality could be collected on day 7 after ovulation in aluteal cycles. Based on the
unaltered embryo recovery rate of aluteal embryos in the present study, we suggest that delayed
tubal-uterine transportation likely did not contribute to the worsened embryo quality observed in
day 8 aluteal embryos as reported previously (Leisinger et al. 2018). The adequate quality of
embryos collected on day 7 in aluteal cycles in our study provides clues that progestagen may not
be as critical for the development of tubal-stage embryos as it is for uterine-stage embryos. In
addition, the embryonic capsule was detected in all embryos in this study, regardless of the
transcript expression of uterocalin (P19) and systemic level of progestagens. These results
indicated that capsule formation requires factors other than uterocalin and progestagens. Therefore,
maternal and embryonic factors facilitating capsule formation in equine embryos warrants further
investigation. As the embryo collected in the aluteal cycle was consistently small with a small
amount of blastocoel cavity, these embryos may serve as potential candidates for cryopreservation
using the conventional slow-freezing method.
The effect of altrenogest supplementation on embryonic development in an aluteal
environment was also characterized. A long-acting injectable altrenogest administered upon
detection of ovulation reverted the developmental delay observed in the aluteal embryos and
induced a favorable endometrial environment on day 7 after ovulation. The transcript expressions
of uteroferrin and uteroglobin in both aluteal (AL) and aluteal-supplemented (AL-Suppl) cycles
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were higher than those in control cycles. In a normal pregnancy, the transcript expressions of
uteroferrin and uteroglobin are highly upregulated and downregulated in the endometrium,
respectively (Hayes et al. 2012). Thus, the significance of the upregulation of these two genes in
embryos collected in both aluteal and aluteal-supplemented cycles remains to be investigated in
future studies. Our study provided evidence that altrenogest supports pregnancies under extreme
hypoluteal conditions. Nonetheless, compromised pregnancy was noted at a later stage on day 24
when pregnancy was solely supported by the long-acting injectable altrenogest. Also, the
appropriate use of altrenogest in a clinically normal equine pregnancy remains to be determined
due to the potential side effect of immune modulation (Fedorka et al. 2019).
We next investigated the hormonal profile in aluteal cycles with or without altrenogest
supplementation and characterized the reproductive parameters in aluteal-induced cycles. In the
aluteal cycle, mares had an increased rate of multiple ovulations and numbers of ovulations.
Although some reports have implicated the administration of prostaglandin F2α (PGF2α) as a factor
leading to the formation of anovulatory follicles, it is remarkable to note that in the present study,
mares in the AL and AL-Suppl cycles received eight serial administrations of 10 mg of dinoprost
that did not lead to increased anovulation events. We conclude that the use of PGF2α, in our study,
the native form of PGF2α (dinoprost) was not associated with the formation of anovulatory follicles.
We also tested an alternative protocol to induce the aluteal cycle and investigated the effect
of continuous administration of exogenous PGF2α for 24 hours on luteal function in mares. While
the constant-rate infusion (CRI) of PGF2α sustained the plasma PGFM level within 24 hours, CRI
of PGF2α was not comparable to the standard antiluteogenic protocol and did not induce an aluteal
cycle.
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Together, the equine aluteal pregnancy model may improve reproductive efficiency by
shortening interovulatory intervals and increasing the rate of multiple ovulations. We speculate
that only a basal level of progesterone might be required for the survival of tubal-stage embryos
and normal tubal-uterine transportation of embryos in mares. Additionally, the long-acting
injectable altrenogest supports early pregnancy adequately and creates a favorable endometrial
environment for at least 7 days in aluteal conditions. However, the treatment regimen with the
long-acting injectable formulation of altrenogest for supporting equine pregnancy requires further
investigation.
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